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ABSTRACT 
 Engineered nanoparticles provide potential opportunities for improving current 
drug delivery, bioimaging and biosensing modalities. In many cases, a ligand, such as a 
protein, peptide or nucleic acids, is attached to the nanoparticles surface to serve as a 
targeting group. However, the nanoconjugation (i.e. covalently bound molecules to a 
nanocarrier) is not an innocuous reaction. It can change the binding affinity and interfere 
with the intracellular trafficking of the tethered species. The understanding of this 
influence to the tethered species is still lacking. Therefore, the main objective of this 
thesis is to investigate the effect of nanoconjugation to the biological identity of the 
tethered biomolecules, in terms of cellular uptake, intracellular trafficking and the 
ultimate biological outcomes.  
 The Epidermal Growth Factor Receptor (EGFR) is a tyrosine kinase that regulates 
cell proliferation and can cause cancer if dysregulated. Continuous treatment with high 
doses of EGF can induce apoptosis, in EGFR overexpressing cell lines. In this thesis, 
Epidermal Growth Factor (EGF) was chosen as the object of investigation. Covalent 
attachment of EGF to gold nanoparticles (NP-EGF) was found to enhance apoptosis in 
EGFR overexpressing cell lines (A431, MDA-MB-468) and it is sufficient to induce 
  vi 
apoptosis in cell lines exhibiting EGFR expression at physiological levels (HeLa). NP-
EGF accumulation through the endosomal pathway was also investigated to assess the 
impact of nanoconjugation on the spatio-temporal distribution of NP-EGF as potential 
origin for the observed enhancement of apoptosis. Two orthogonal experimental 
approaches were applied: (1) isolation of NP-EGF containing endosomes by taking 
advantage of the increased density of endosomes associated with the uptake of Au NPs; 
(2) correlated darkfield/fluorescence imaging to map the spatial distribution of NP-EGF 
in endosomes as a function of time. The studies reveal that nanoconjugation prolongs the 
dwelling time of phosphorylated receptors in the early endosomes and that the retention 
of activated EGFR in the early endosomes is accompanied by an EGF mediated apoptosis 
at effective concentrations that do not induce apoptosis in the case of the free EGF. 
 Investigating the nanoconjugation-enhanced EGF-induced apoptosis improves the 
current understanding of cell-nanomatieral interactions and provides new opportunities 
for overcoming apoptosis evasion by cancer cells. 
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CHAPTER 1 Introduction 
1.1 Nanoconjugation Influences Ligands Distribution and Signaling 
 Application of engineered nanoparticles (NPs) in bioimaging, drug delivery and 
biosensing (Davis, Chen et al. 2008; Murphy, Gole et al. 2008; Sun, Lee et al. 2008; Nel, 
Madler et al. 2009) has spread rapidly over the past few decades. The fundamental 
distinct features of the nanoscale materials, such as small size, large surface-volume ratio 
and high electron confinement, compared with materials in bulk, result in many superb 
biophysical and biochemical properties (Kamat 2002; Albanese, Tang et al. 2012; 
Dreaden and El-Sayed 2012).  
 One of the interesting properties of these engineered NPs is the ability for targeted 
delivery of nanocarriers to specific areas of interest. For example, in many tumor cells, 
the vasculature is architecturally defective to increase the permeability due to the need of 
nutrients and oxygen accumulation to sustain rapid growth. Macromolecules that are 
larger than 50 kDa can leak out from the tumor vessels and selectively concentrate in the 
tumor sites and exhibit a prolonged circulation time and slow clearance. (Cho, Wang et al. 
2008; Fang, Nakamura et al. 2011; Brannon-Peppas and Blanchette 2012) This 
phenomenon is usually referred to as the enhanced permeability and retention (EPR) 
effect. It is size dependent and as a result, NPs ranging from few nanometers to few 
hundred nanometers can leak from the vesicular bed and passively accumulate in the 
interstitial space of the tumor area. However, since EPR effect is based on the 
permeability of tumors, in the poorly permeable tumors, in particular the central regions 
of metastatic cancers, are difficult to reach with nanoparticles. Even more so, 
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accumulation of NPs within the tumor tissue doesn’t necessarily lead to internalization of 
cargos into tumor cells since the latter is a highly spatio-temporal membrane mediated 
process (Master and Sen Gupta 2012). Therefore, besides this passive targeting, ligand-
mediated active targeting is often adopted in engineered NPs to increase the specificity 
and in many cases facilitate endocytosis to deliver cargos into intracellular organelles. 
(Moghimi, Hunter et al. 2001; Kolb and Sharpless 2003). To achieve this goal, NPs are 
functionalized with a specific ligand, such as proteins, peptides, nucleic acids or small 
molecules, which is capable of recognizing specific markers on the cellular surface to 
preferentially facilitate accumulation in the targeted areas. For example, in cancer therapy, 
NPs coated with transferrin or epidermal growth factor receptor antibody have been 
shown to be successful in tumor cell targeting and internalization.(Derycke and De Witte 
2002; Mamot, Drummond et al. 2003; Hatakeyama, Akita et al. 2004; Mamot, Ritschard 
et al. 2006; Hong, Zhu et al. 2009; Master and Sen Gupta 2012)  
 However, the covalent attachment of biomolecules to a nanocarrier is not an 
innocuous reaction. In fact, nanoconjugation has been shown to influence ligand cell 
interaction and alter the intracellular trafficking of the surface ligand in many studies 
(Bhattacharyya, Bhattacharya et al. 2010; Wang, Tian et al. 2010; Wu, Yu et al. 2014). 
The mechanism of endocytosis and subsequent trafficking of nanoconjugated 
biomolecules is expected to depend both on the nature of the biomolecule and NP related 
parameters (size, shape, surface composition and charge). Jiang et al. found that 
Herceptin coated Au NPs and Ag NPs can regulate cellular uptake of its receptor, 
epidermal growth factor receptor 2 (HER2), and it strongly depended on nanoparticle size 
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(Jiang, Kim et al. 2008). Bhattacharyya et al. reported a faster internalization and distinct 
endosomal accumulation of EGFR with nanoconjugated cetuximab, a monoclonal anti-
EGFR antibody (Bhattacharyya, Bhattacharya et al. 2010). Lee et al. found that 
nanoconjugation of epidermal growth factor receptor 2 binding aptamer achieves an 
enrichment of the NP-HER2 complex in the lysosomes followed by a downregulation of 
HER2 and resulting in anticancer effects (Lee, Dam et al. 2015). These findings showed 
that nanoparticles cannot be taken as simple carriers but can also actively interact with 
biological processes.  
 Although NPs provide potential leverage for interfering with the biological 
processes and for manipulating cell responses, the influence of nanoconjugation to the 
tethered moieties on nanoparticles surface is not well understood. One possible 
explanation comes from the distinct feature of the designable presentation of ligands on 
NPs surface compared with free ligands (Mammen, Choi et al. 1998; Gestwicki, Cairo et 
al. 2002). The ability of tuning the size, shape and ligand density of NPs presents 
different architectures of the biomolecules and as a result influences the interaction 
between surface ligand and the cellular receptors in a controlled manner. It can serve both 
as potent inhibitors or effectors in biological processes (Klemm, Schreiber et al. 1998; 
Kiessling, Gestwicki et al. 2000; Gestwicki, Cairo et al. 2002). The multiple ligands 
present on the surface can increase the binding affinity and thus block the binding sites 
effectively. In other cases, presentation of multiple ligands can also induce or block 
dimerization or oligomerization of receptors to promote or depress a specific biological 
response through cellular signal transduction. Huang et al. tethered dinitrophenyl (DNP) 
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to gold nanoparticles of different sizes and at varying ligand densities and found that 
changing these parameters was capable of regulating the process of antibody-receptor 
binding and cross-linking and further manipulating biological outcomes (Huang, Liu et al. 
2009). Paviolo et al. exclusively conjugated epidermal growth factor to the tips of gold 
nanorods. By tuning the length of nanorod they could selectively choose to facilitate or 
block the dimerization of the receptors and as a result promote or inhibit cell proliferation 
(Paviolo, Chon et al. 2015). Wang et al. observed an increased caspase 3/7 activity due to 
the multivalent presenting of transferrin and a distinct endocytosis and trafficking of 
nanoconjugated transferrin in the intracellular acidic compartments, which showed 
negative in EEA-1(early endosomes maker) and LAMP-1 (lysosomes marker) staining. 
(Wang, Tian et al. 2010). 
 Therefore, although the initial aim of covalently attaching a biomolecule to the 
nanoparticles is to utilize its specificity to facilitate the accumulation of the nanocarriers 
to an interested region, nanoconjugation cannot be taken as an innocuous reaction. It has 
also the potential to considerably change the ligand behavior and to alter cell ligand 
interaction. These changes provide unique opportunities to manipulate cellular processes, 
given that they can be controlled in a rational fashion. Detailed studies of how 
nanoconjugation influences the function of the tethered species are necessary to utilize 
these effects in future therapeutics and will, furthermore, contribute to improve the 
understanding of nano-bio interface, in general. 
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1.2 Epidermal Growth Factor Receptor 
 The plasma membrane separates the interior of cells from the environment and it 
is a key barrier that NPs encounter when they interact with cells. Among the various 
biomolecules presented on cell surface, transmembrane proteins that have a tyrosin 
kinase domain in the intracellular region (receptor tyrosin kinase, RTK) play a crucial 
role in cellular communication and regulate many fundamental cellular processes such as 
cell migration, cell cycle control, cell proliferation and differentiation (Hubbard and Till 
2000; Schlessinger 2000; Lemmon and Schlessinger 2010). Mutations of RTKs and 
abnormal activation of signaling are causally associated to many human diseases such as 
cancers, diabetes and angiogenesis (Blume-Jensen and Hunter 2001; Normanno, De Luca 
et al. 2006).  
 Among the 58 known human RTKs, epidermal growth factor receptor (EGFR) is 
a prominent member and one of the best characterized RTKs (Carpenter 1987; Ullrich 
and Schlessinger 1990). It is a 170 kDa glycoproteins that has an extracellular ligand 
binding domain, a transmembrane alpha-helical segment and a cytoplasmic domain of 
tyrosine kinase. Eight EGFR ligands have been discovered: epidermal growth factor 
(EGF), transforming growth factor-α (TGF- α), amphiregulin (AREG), epiregulin 
(EREG), neuregulin (NRG), β-cellulin (BTC), epigen (EPGN) and heparin-binding EGF-
like growth factor (HBEGF) (Schneider and Wolf 2009). Upon ligand binding, 
conformational change of the extracellular domain of EGFR gives rise to receptor 
dimerization or higher order cluster formation to initiate an autophosphorylation of 
multiple residues in cytoplasmic tail (Yarden and Sliwkowski 2001; Schlessinger 2002; 
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Sorkin and Goh 2009) and as a result triggers the downstream signaling cascades 
including the phosphoinositide-3-kinase (PI3K) pathway, mitogen activated protein 
kinase (MAPK) pathway, and the phospholipase Cγ pathway depending on the ligand 
type and concentration which further lead to distinct biological end effects (Fischer, Hart 
et al. 2003; Scaltriti and Baselga 2006). In cells with physiological level of EGFR 
expression, after ligand binding, the activated EGFR is internalized into cells through a 
fast clathrin-dependent endocytosis and routed to early endosomes where the receptors 
fate is decided: recycle back to the plasma surface or go further down through the 
endosomal pathway to late endosomes and lysosomes where they are degraded (Chinkers, 
McKanna et al. 1979; Haigler, McKanna et al. 1979; Yamazaki, Zaal et al. 2002; 
Sigismund, Argenzio et al. 2008; Sorkin and Goh 2009). An alternative pathway has also 
been observed which is insensitive to clathrin under the condition of high EGF 
concentration (Aoki, Nomura et al. 1999; Coller and Paulnock 2001; Hambleton, 
Steinberg et al. 2007). Although the majority of signaling events occur on the plasma 
membrane (Brankatschk, Wichert et al. 2012; Sousa, Lax et al. 2012; Tomas, Futter et al. 
2014) and the internalization of the active receptors is believed as a part of the 
attenuation of signaling, EGFR-mediated signaling can continue from early endosomes 
since the EGFRs remain dimerized with phosphorylated RTK domain exposed to the 
cytoplasm after internalization (Sorkin and von Zastrow 2009; Tomas, Futter et al. 2014; 
Villaseñor, Nonaka et al. 2015). The signaling is terminated either by maturation of early 
endosomes into late endosomes where the phosphorylated cytoplasmic tails are 
sequestered in the intraluminal membranes of the multivesicular bodies (MVBs) (Wang, 
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Pennock et al. 2002) or by dephosphorylation through a protein tyrosin phosphatase 
(Tiganis 2002; Tomas, Futter et al. 2014). EGFR signaling cascade is under highly spatial 
and temporal regulation and therefore dysregulation of which can result in increased 
proliferation and invasive ability, tumor angiogenesis, metastasis, and apoptosis evasion. 
(Normanno, De Luca et al. 2006; Schneider and Wolf 2009; Lemmon and Schlessinger 
2010). Abnormal EGFR activation appears to be an important factor in tumorigenesis, 
and is causally related to the aggressive growth behavior of cancer. Table 1 summarizes 
the EGFR expression level and overall survival rates. The elevated levels of the EGFR 
have been found as a common feature of various cancer types and act as a strong 
prognostic indication (Nicholson, Gee et al. 2001; Herbst and Shin 2002; Naik, Sharma et 
al. 2011; Soonthornthum, Arias-Pulido et al. 2011).  
Cancer Type 
Tumor 
Overexpressing 
EGFR 
Overall 
Survival 
Reference 
Bladder 27%-75% 63% (n=11) 
Nicholson, Gee et al. 2011; 
Naik, Sharma et al. 2011 
Cervical 19%-90% 71% (n=7) 
Nicholson, Gee et al. 2011; 
Soonthornthum, Arias-
Pulido et al. 2011 
Head and Neck 80%-100% 82% (n=11) Nicholson, Gee et al. 2011; 
Herbst, Shin. 2002 
Ovarian 35%-70% 67% (n=9) Nicholson, Gee et al. 2011; 
Herbst, Shin. 2002 
Breast 14%-91% 55% (n=11) Nicholson, Gee et al. 2011; 
Herbst, Shin. 2002 
Non-small-cell 
lung cancer 
40%-80% 10% (n=10) Nicholson, Gee et al. 2011; 
Herbst, Shin. 2002 
 
Table 1.1. EGFR Expression Level and Association with Overall Survival.  
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 One of the key natural ligands of EGFR is EGF. It is a roughly 6kD peptide of 53 
amino acids containing six cysteines. This low molecular weight, heat stable peptide was 
first found in the extracts of the submaxillary gland of the mouse which induced eyelid 
opening when injected to newborn animals in early 60s. A decade later, the human form 
of epidermal growth factor was isolated from human urine and was found in many human 
tissues since then (Carpenter and Cohen 1979). In physiological environment, binding 
EGF to EGFR on cellular surface leads to cell growth, proliferation and differentiation 
(Sorkin and von Zastrow 2009; Tomas, Futter et al. 2014). However, interestingly, an 
EGF-induced apoptosis is observed as a result of spatial disruption of the trafficking of 
the activated complex of EGF and EGFR (Gulli, Palmer et al. 1996; Hognason, 
Chatterjee et al. 2001; Lehto 2001; Chen, Huang et al. 2004). In those cases, cells with 
overexpression level of EGFR such as epidermoid carcinoma (A431) or basal-like breast 
cancer (MDA-MB-468) cells are treated with high concentration of EGF that results in a 
saturation of cellular trafficking machinery and an accumulation of activated EGFR in the 
limited membrane of early endosomes leads to a delay of signal termination. This 
disruption of the spatially and temporally well-orchestrated distribution of EGF-EGFR 
complex trafficking triggers apoptosis (Rush, Quinalty et al. 2012).  
1.3 Nanoconjugation: a material approach to manipulate cellular processes 
 In summary, it has been shown that the biological end effect from EGFR 
stimulation sensitively depends on the temporo-spatial distribution of EGF-EGFR 
complex and a careful design of the NPs could provide some leverage to manipulate the 
cellular processes and trafficking of the tethered functionality. Therefore, it is intuitive to 
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hypothesize that the temporo-spatial regulation of endosomal EGFR signaling makes the 
signaling outcome susceptible to intervention via nanoconjugation. In this thesis, the 
influence of nanoconjugation on the apoptotic efficacy of EGF was quantified. The size 
dependence of the nanoconjugation effect was also investigated. Since the EGFR 
regulation and signaling is sensitive to the temporo-spatial distribution of the EGF-EGFR 
complex, the accumulation of NP-EGF through the endosomal pathway was carefully 
studied as a potential origin of the observed change in biological outcome for 
nanoconjugated EGF.  
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CHAPTER 2 Engineering Nanoconjugated EGF 
2.1 Biomedical Application of Gold Nanoparticles 
 Gold, a group 11 element with atomic number 79, was one of the first noble 
metals discovered, mined and used by human beings which dates back thousands years 
ago. Early civilization such as China and Egypt knew or at least used colloidal gold 
nanoparticles for medical and aesthetics purpose around 5th-4th century B.C. They were 
and are still in use for coloring glasses and ceramics. In the middle age Europe, 
alchemists used and studied colloidal gold and believed it had outstanding ability to cure 
many diseases such as mental disorder and syphilis as well as capable of prolonging 
lives. (Dykman and Khlebtsov 2012) 
 Modern scientific study of colloidal gold particles did not take place until Michael 
Faraday first successfully prepared pure sample of colloidal gold by reducing gold 
chloride with phosphorus in aqueous phase in the 1850s (Edwards and Thomas 2007). He 
announced this important discovery in his Bakerian lecture at the Royal Society in 
London. Although at that time the exact size of gold nanoparticles was unknown, it was 
believed that they were small and could interact with light (Thomas 1988).  
 Despite the long history of gold colloidal particles, the application of gold particle 
in biological research began from 1971, when W. P. Faulk and G. M. Taylor conjugated 
antibodies with colloidal gold and visualized them in the electron microscope (Faulk and 
Taylor 1971; Geuze, Slot et al. 1981). From then on, the medical and biological 
application of Au NPs has once again aroused interests due to the tenability and precise 
control of the size and morphology  (Daniel and Astruc 2004; Ziegler and Eychmuller 
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2011; Zhao, Li et al. 2013), excellent surface chemistry which can be used to easily 
introduce different surface properties (Love, Estroff et al. 2005; Sapsford, Algar et al. 
2013), superb optical features which are beneficial to the diagnostic and therapeutic 
purposes (Murphy, Gole et al. 2008; Dreaden, Alkilany et al. 2012) and low toxicity 
which is required in biomedical applications (Shukla, Bansal et al. 2005; Murphy, Gole et 
al. 2008; Dreaden, Alkilany et al. 2012).  
 In general, Au NPs are synthesized by reducing HAuCl4 in the presence of 
stabilizing ligands. Various methods have been developed and applied to synthesize Au 
NPs in wide size range with narrow distribution. They are mainly based on two major 
protocols. One was reported by Turkevich and Frens in which citrate is utilized to reduce 
and stabilize gold nanoparticles in aqueous solution. It is capable of controlling Au 
spheres size from 10 nm to few hundreds nm with narrow distribution (Turkevich, 
Stevenson et al. 1951; Frens 1973; Shukla, Bansal et al. 2005). Another popular method 
is based on two-phase approach developed by Brust and Schiffrin in which 5-6nm Au 
NPs can be synthesized in organic solvent that are not normally miscible with water. An 
aqueous reductant, phase transfer catalysts and a stabilizing thiol ligand in organic phase 
are used in these methods (Brust, Walker et al. 1994). Moreover, various shapes with 
narrow distribution can be achieved for Au NPs. A seed mediated growth is commonly 
adopted to generate different morphologies (Grzelczak, Pérez-Juste et al. 2008; Xia, 
Xiong et al. 2009). In the first step, small uniform spherical gold seed particles (size 
between 1 to 5 nm) are prepared. The reaction environment is subsequently changed. 
Different reductants and shape templating surfactants or molecules are added. As a 
  
12 
consequence, the gold seeds grow to a larger size with desired morphologies. For 
example, in the gold nanorod case, 1.5 nm hexadecyltrimethylammonium bromide 
(CTAB) protected Au seeds is first prepared and then further grows in the aqueous 
solution of HAuCl4, CTAB, AgNO3 and ascorbic acid to generate a high yield of single 
crystalline Au NPs with aspect ratio of 2 to 5 (Lohse and Murphy 2013). Other examples 
also include: nanocubes, nanostars, nanowires and nanoshells etc.  
 The surface functionalization of Au NPs is mainly based on Au-thiol chemistry. 
Thiols and disulfides are used to form covalent bound to Au NP surface. The current 
widely accepted mechanism of this Au-thiol chemisorption is through the thiyl. Reaction 
is like to occur with reductive elimination of the thiol hydrogen or cleavage S-S bond in 
disulfides creating formally thiyl. The protonated SH group can also form weakly 
coordination bonding with gold through the sulfur lone pair electrons (Häkkinen 2012). 
The hemolytic Au-S bond strength is ~ 40-60 kcal/mol, which is close to that of the gold-
gold bond. In most cases, the ligation is very fast and spontaneously occur at room 
temperature (Love, Estroff et al. 2005). Therefore, heterobifunctional thiol molecules are 
commonly used to functionalize Au NPs and to tether biological molecules (Figure 2.1). 
The thiol or disulfide is used to attach the molecule to the Au surface. The other terminus 
is usually a functional group which is introduced to 1). link with biomolecules or/and 2). 
provide surface properties (e.g. charge). The linker between thiol and functional group 
serves as a spacer between the tethered biomolecules and Au surface to provide control 
over relative separation distance from nanoparticle, increase accessibility and flexibility 
of the biomolecules and in some cases modify surface properties as well. One of the 
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commonly used spacers is biological inert polyethylene glycol (PEG). It can be prepared 
in various lengths and confer greater water solubility to facilitate biomedical applications. 
 
 
Figure 2.1. Functionalization of Au NPs. 
 
 Moreover, Au NPs have exquisite optical properties and can be imaged in optical 
scattering or photothermal microscopy without any blinking or bleaching and with no 
physical limitation in observation time (Murphy, Gole et al. 2008; Dykman and 
Khlebtsov 2012; Wu and Reinhard 2014). The optical properties are determined by 
conduction band electrons which exhibit collective oscillation in response to an external 
electromagnetic field (Figure 2.2). At the localized surface plasmon (LSP) resonance 
(LSPR) frequency the surface charge density oscillations form a standing wave so that 
even weak incident E-fields achieve large charge accumulations. The LSPRs of Au NPs 
lie in the visible range of the electromagnetic spectrum and can be continuously tuned to 
the near IR range by changing the size and morphologies. Since the polarizability of a NP 
is resonantly enhanced at the LSPR, scattering and absorption cross-sections, as a result, 
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become maximum at this frequency. The strong charge concentration in a small volume 
on the surface of the NP creates a strong local E-field enhancement at the LSPR and it 
can be used as a bright probe with long monitoring time (Wu and Reinhard 2014).  
 
 
Figure 2.2. Optical Properties of Au NPs.  
Left: Light incident onto a metal NP creates charge density oscillations on the surface. Right: A plot of the 
optical powerflow around a noble metal NP at the LSPR frequency shows a rerouting of the incident light 
towards the NP. Figure adapted with permission from Wu L. et al., Chem. Soc. Rev., 2014, 43, 3884-3897 
 
 Low toxicity is an important aspect in designing nanoparticles. Many groups have 
tested the toxicity of Au NPs. Connor et al tested the cytotoxicity of a series Au 
nanospheres of different size (4, 12 and 18 d.nm) and surface properties (anionic, neutral 
and cationic). None of them were toxic to the human leukemia cells at a concentration up 
to around 100 µM (Connor, Mwamuka et al. 2005). Shukla et al. also showed that Au 
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nanospheres of 3.5 nm are not cytotoxic and do not stimulate secretion of inflammatory 
cytokines in macrophage (Shukla, Bansal et al. 2005). On the contrary, other groups have 
observed toxicity of Au NPs. Goodman et al studied the toxicity of 2 nm Au NPs with 
cationic and anionic surface and found that the cationic gold nanoparticles are in general 
toxic at a lower concentration than anionic Au NPs (Goodman, McCusker et al. 2004). 
Pan et al found that 1.4 nm gold nanospheres can induce necrosis in all the cell lines they 
examined while no toxicity was brought by 15 nm Au nanospheres of similar surface 
composition (Pan, Leifert et al. 2009). Contradicting observations may rise from the 
different experimental conditions like incubation time, particle concentration and the type 
of cell lines. While nearly everything is undoubtedly toxic at some concentration, the 
argument of the gold nanoparticles toxicity should be based on the potential 
concentration at which they might be used. The previous studies have shown that the 
toxicity of nanoparticle depends on particle size and surface chemistry and thus provide 
potential leverage by designing Au NPs nontoxic. 
 Therefore, Au NPs make a good candidates for our application where precise size 
control, tunable surface properties and lower toxicity of the carriers are required. Two 
sizes of Au NPs were employed in the following experiments: 40nm and 80nm.  
2.2 Design and Synthesis of Nanoconjugated EGF 
 A scheme of the NP design used in this work is given in Figure 2.3. 
Heterobifunctional thiol PEGs were used to: 1). modify the surface properties; 2). 
introduce EGF; 3). provide a spacer to increase the accessibility and flexibility of EGF. 
Specifically, we functionalized 40nm and 80 nm diameter Au NPs with HS-PEG77-N3 
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(PEG1) and HS-(CH2)11-EG6-COOH (PEG2) in a nominal ratio of 1:1. The azido group 
in PEG1 was used to tether alkyne-modified EGF to the NPs through the CuI catalyzed 
azide alkyne Huisgen cycloaddition (Kolb, Finn et al. 2001; Kolb and Sharpless 2003). 
Azides and alkynes are both relatively inert to biological molecules and physiological 
environment. With presentation of CuI, the cycloaddition reaction rate dramatically 
increased in aqueous solution at room temperature (Kolb and Sharpless 2003). The 
shorter PEG2 was introduced to stabilize the NPs by electrostatic repulsion and to 
increase the accessibility of the azido group on the surface. In this way, a presentation of 
EGF with a high degree of conformational flexibility and surface accessibility can be 
achieved.  
 
 
Figure 2.3. Schematics of NP-EGF Preparation.  
Au NPs are first functionalized with PEG1 (=HS-EG77-N3) and PEG2 (=HS-(CH2)11-EG6-COOH) to 
introduce binding sites and stabilize the NPs respectively. Functionalized human EGF is then covalently 
linked to PEG1 through the CuI catalyzed azide alkyne Huisgen cycloaddition. Figure adapted with 
permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-166. 
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 For EGF, propargyl group is introduced through the crosslinking of propargyl-
PEG-NHS ester and primary amine in the peptide.  
 Citrate stabilized 40nm or 80nm Au NPs were synthesized through the Turkevich 
method to generate Au colloidal solution at a concentration of 9×1010 particles/mL. 
PEG1(10 mM, 5 µL) and PEG2 (10 mM, 5 µL) were added to 4 mL of Au NP colloid to 
yield a concentration of 25 μM for each PEG and then incubated for around 17 h at room 
temperature before they were washed three times by centrifugation and resuspension in 
DI water (2400 rpm, 10 min). The final NP-PEG pellets were resuspended in 770 μL of 
0.5 X PBS. Propargyl-PEG-NHS ester solution in DMSO (100 mg/mL, 2 μL) was added 
to an aqueous solution of EGF (1mg/mL, 100 μL) in 1 X PBS, pH 7.4, and incubated at 4 
°C for 6 h. This mixture was then dialyzed against 0.5 X PBS for 48 h to remove 
unreacted propargyl-PEG-NHS ester. The obtained propargyl-PEG-EGF (20 μL) was 
then added to NP-PEG (770 μL) in the presence of 500 μM ascorbic acid and 100 μM 
CuSO4 as catalysts and incubated at 4 °C overnight. The resulting NP-EGF particles were 
dialyzed against 0.1 X PBS for 48 h and then washed further through centrifugation and 
resuspension (twice, 2200 rpm, 10 min). The NP-EGF prepared as described above was 
then characterized prior to use. 
2.3 Characterization of NP-EGF 
 The hydrodynamic diameter and zeta potential of NPs through the preparation 
process were measured by dynamic light scattering (DLS, Malvern Zetasizer ZS90) as 
show in Table 2.1. Increases of hydrodynamic size of Au NPs were observed after each 
step in Au NPs functionalization. For 40nm Au NPs, the hydrodynamic diameter 
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increases from 38 nm to 48.4 ± 0.6 nm after pegylation which further increases to 56.1 ± 
2.5 nm upon introduction of EGF to the surface. Simple mixtures of pegylated NPs and 
EGF (no covalent attachment) without catalyst (CuI) didn’t lead to size increase with 
DLS measurement. The measured hydrodynamic diameter of NPs in this case was 47.8 ± 
1.3 nm nearly identical to that of the pegylated NPs. For 80nm Au NPs, the size increases 
to 103.4±1.2 nm in pegylation step and further increases by 9 nm to 112.3 ± 3.2 nm after 
tethering with EGF. The functionalized NPs are monodispersed and with narrow 
distributions (polydispersity Pdi < 0.1). The zeta potential of NPs are in general negative 
which comes from the carboxylic acid group in PEG2. 
 
 
Hydrodynamic 
Diameter (nm) 
Zeta Potential 
(mV) 
EGF Density 
(EGF / NP) 
40 nm Au 
NPs 
NP-PEG 48.4 ± 0.6 -64.3±9.02 N.A. 
NP-EGF 56.1 ± 2.5 -54.3±8.97 4±1 
80 nm Au 
NPs 
NP-PEG 103.4±1.2 -54.9±11.1 N.A. 
NP-EGF 112.3±3.2 -47.4±9.78 124±16 
 
Table 2.2. Characterization of Au NPs.  
NP-PEG (before conjugated with EGF) and NP-EGF were prepared. Hydrodynamic diameter and zeta 
potential of NPs were measured with DLS. EGF surface density was measured with ELISA. N.A.: not 
applicable.  
 
 The average number of EGF molecules bound per NPs were quantified through an 
ELISA assay. To that end, The PEG1-EGF construct was removed from the purified NP-
EGF by incubation in a large excess of PEG2 and then purified before assayed in EGF 
ELISA. PEG2 (20μL, 10mM) was mixed with NP-EGF (20μL, 6×1011NPs/mL) in 1X 
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PBS, pH 7.4 at 45°C for 2 days and the mixture was sonicated every 12h to achieve 
efficient replacement of surface bound ligands by PEG2. After that, the particles were 
spun down and the supernatant was collected. ZebaTM spin desalting columns were 
applied to clean the collected EGF-PEG1 constructs and to remove excess PEG2. The 
purified EGF-PEG1 constructs were diluted by a factor of 50 with 1X PBS. The ELISA 
quantification of EGF requires a standard of known concentration. PEG1-EGF conjugates 
were used for that purpose. Solutions of propargyl-PEG-EGF (90μL, 66μM) and PEG1 
(10μL, 7.3mM), both in 0.5X PBS were mixed in the presence of  ascorbic acid (500μM) 
and CuSO4 (100μM) and then incubated for overnight at 4°C, resulting in a solution 
containing PEG1-EGF at a concentration of 0.36 mg/mL (59 μM). ZebaTM spin desalting 
columns were then applied to clean the PEG2-EGF construct. After that, the human EGF 
ELISA kit was used to determine the concentration of PEG1-EGF through the 
colorimetric reaction between peroxidase and tetramethylbenzidine. 100 μL samples and 
standards were first incubated in the 96 well dish which is prior immobilized anti human 
EGF antibody for 2 h at room temperature. 96 well dish was then washed 4 times with 
washing buffer before 100 μL detection biotinylated anti-human EGF antibody was 
added to wells and further incubated for 1.5-2 h at room temperature. After 4 times wash 
with washing buffer, 100 μL HRP-Streptavidin was added and incubated for 30 min at 
room temperature and washed away before adding 50 μL tetramethylbenzidine and 
incubated no longer than 20min before 2 mol/L H2SO4 were added to stop the reaction. 
For 40 nm NP-EGF, 4 ± 1 EGF per NP-EGF is achieved and the surface density increase 
to 124 ± 16 EGF per NP-EGF of 80 nm Au NPs. Validation of this ELISA method was 
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achieved with TEM studies, in which EGF molecules on individual NP-EGF were 
visualized after labeling with biotinylated 5 nm diameter Au NPs through biotin 
Neutravidin interaction (Figure 2.4). Biotinylated 5 nm Au NPs were first prepared. HS–
CH2CH2–(CH2CH2O)54–N3 (PEG3) and HS–CH2CH2– (CH2CH2O)16–Biotin (PEG4) 
were added to 1 mL of commercial 5 nm Au NP (∼5 × 1013 particles per mL) colloid to 
yield a concentration of 220 μM for PEG3 and 24 μM for PEG4 and then incubated 
overnight at room temperature. The PEGylated 5 nm Au NPs were purified through 5 
times filtration with 100 kDa centrifugal filters and then transferred into 1X PBS. A NP-
EGF solution was incubated on a carbon type B coated gold TEM grid for 30 min and 
then removed. The surface was blocked with 10% bovine serum albumin (BSA) in 1X 
PBS on the grid for 2 h at 4 °C. After removal of the BSA solution, the surface was 
washed 5 times with 1X PBS. Then, a solution of a biotinylated anti-EGF antibody was 
incubated on the grid overnight at 4 °C. The grid was then washed 5 times with 1X PBS 
and a 10 µg/mL solution of Neutravidin containing 1% BSA in 1X PBS was incubated 
with the sample for 1 hour at room temperature. The sample was washed 5 times and the 
solution of biotinylated 5 nm Au NPs (1015 particles per mL) in 1X PBS was incubated 
with the sample for 2 h at room temperature. A control sample was made using the same 
procedure, but without the anti-EGF antibody incubation step. The samples were then 
washed 3 times with 1X PBS (15 min each), finally thoroughly rinsed with ddi water and 
subsequently air-dried. The samples were imaged using a JEOL JEM 2010 high-
resolution transmission electron microscope (HRTEM) with 200 kV acceleration voltage. 
In this way, a satellite structure of 40 nm NP-EGF probed by 5 nm Au was achieved. The 
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number of the smaller 5 nm Au NPs reflected the number of surface ligand of EGF. 
Approximately 90 Au cores were analyzed. TEM analysis results were consistent with 
ELISA (Figure 2.4 a,b). The maximum number of bound 5 nm labels was 12, the average 
was 2.7 EGF per Au NP, while it is negligible in control group. Based on geometric 
considerations, we estimate that approximately 45% of all bound 5 nm NP labels are 
detectable in conventional TEM. The remaining NP labels are located in areas where the 
diameter of the smaller NP is entirely blocked by the larger core so that the contrast is 
insufficient for their detection. Taking this effect into account, one can anticipate that the 
average number of bound 5 nm Au labels is around 6, which is in good agreement with 
the ELISA assay. 
 
 
Figure 2.4. Visualize Surface EGF of 40 nm NP-EGF.  
a, b. TEM image of NP-EGF conjugates after incubation with biotinylated anti-EGF antibodies and 
Neutravidin and subsequent labeling with biotinylated 5 nm Au NPs. c,d. TEM images of control 
experiments using the same particles but without the anti-EGF antibody. e. Box plot of the number of 5 nm 
NP labels detected on NP-EGF (left) and control (right). The TEM data confirm a selective binding of 5 nm 
NP labels to NP-EGF. Figure adapted with permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-166. 
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Figure 2.5. Stability of 40 nm NP-EGF.  
NP-EGF conjugates incubated with the cells in serum containing DMEM for 4 h before they were washed 
through centrifugation (3600rpm, 15min) and resuspended in 0.5x PBS. a. UV-Vis spectra of NP-PEG (red) 
and NP-EGF before (yellow) and after (blue) incubation. b. SEM images of NP-EGF conjugates before 
(left) and after incubation (right). All particles were randomly deposited on a silicon substrate through 
incubation for 1h. Subsequently the silicon chips were washed with ddi water and dried before imaging in 
SEM. The UV-Vis spectra and the SEM images confirms the stability of NP-EGF against agglomeration. 
Figure adapted with permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-166. 
 
 Stability is an important aspect in engineering NPs. The complex nature of the 
physiological environments present high ionic and serum concentrations which is capable 
of weakening the stability of NPs and form large aggregates (Dreaden, Mackey et al. 
2011). Formation of large aggregates directly influences the monodispersity, 
concentration and binding efficiency of the nanomaterials. Therefore, the stability of NP-
EGF at the experimental condition was also studied for both sizes under physiological 
environment. 40 nm NP-EGF (60 pM) was incubated with A431 cells in serum-
containing DMEM medium for 4 h at 37˚C and NPs were then recovered from the 
solution by centrifugation (twice, 5000 rpm, 0.1 X PBS). The measured UV-Vis spectrum 
(Figure 2.5a) superimposes almost perfectly with that of NP-EGF recorded prior to 
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incubation with the cells. Scanning electron microscopy (SEM) was also utilized to study 
the monodispersity of NP-EGF after incubation with cells. Recovered NP-EGF were 
deposited on a silicon substrate and checked with SEM (Zeiss Supra 40VP). Consistent 
with UV-Vis data, the SEM images (Figure 2.5b) show predominantly monomers before 
(94.1%) and after (93.5%) incubation with the cell confirming a high degree of stability 
of 40 nm NP-EGF in serum-containing DMEM. For 80 nm NP-EGF, the stability of NP-
EGF in DMEM at 37 °C was tested by monitoring the average hydrodynamic diameter 
using DLS (Figure 2.6). 80 nm NP-EGF was suspended in DMEM with a final 
concentration of 8 pM and incubated at 37 °C for the indicated time and the size of NP-
EGF was checked. There was no significant agglomeration of NP-EGF within at least  
 
Figure 2.6. Stability of 80 nm NP-EGF.  
Stability of NP-EGF. NP-EGF was suspended in DMEM at 37 °C for durations as indicated before DLS 
data were collected. Before 4 h, the hydrodynamic diameter of NP-EGF was barely changed. After 6 h, 
there was an obvious shift of the peak and after 24 h, a population of agglomerates were found in the few 
thousand nm area.  
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first 4 h. However, after 6 h, an observable peak shift appeared and after 24 h incubation 
in the growth medium at 37 °C, the NP-EGF showed a new peak in the large size range 
due to agglomeration. Therefore, incubation times of 80 nm NPs with cells was chosen ≤ 
4h in all subsequent experiments. 
 From the DLS zeta potential measurement, for both size, NP-EGF and NP-PEG 
show negative surface charges in aqueous solution under physiological pH conditions due 
to the acid PEG (PEG 2) used for NP stabilization. The negative charge will, 
consequently, attract positively charged components in the physiological environment 
where the experiments described in the following chapters were conducted. The 
attachment of proteins onto the NP surface will lead to the formation of a protein 
“corona” around the NPs with different physico-chemical properties and is potentially 
capable of influencing the interaction between NPs and cells. Therefore, the 
bioavailability of nanoconjugated EGF under the chosen experimental conditions was 
validated by quantifying the EGF-specific cellular binding and uptake of NP-EGF and 
measuring the resulting global EGFR activation. Cellular binding and uptake were 
quantified with inductively coupled plasma mass spectrometry (ICP-MS, VG Plasma 
Quad ExCell), a useful tool to quantify Au atom concentration with low detection limit 
(0.05 ppb) (Li, Zhao et al. 2010). In these measurements, Au NPs were first digested with 
aqua regia to form chloroaurate anions (AuCl4
−). Au concentration was then quantified 
with ICP-MS and converted the number of Au atoms back to the number of Au NPs with 
following equation (Chithrani, Ghazani et al. 2006):  
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where D is the diameter of the sphere Au NP, U is the number of Au atoms in each Au 
sphere of the defined size D, a is the cubic face with cell parameters of 4.0786 Å and M 
is the number of Au atom measured with ICP-MS. The global EGFR activation was 
determined by the phosphorylation level of EGFR after cells were treated with different 
conditions using the traditional ELISA assay.  
 
 
Figure 2.7. Bioactivity and Accessibility of 40 nm NP-EGF.  
a. Relative Au concentrations (normalized to maximum) as determined by ICP-MS after incubation of 
A431 cells with 0.06 nM solutions of (left to right) pegylated Au NPs, pegylated Au NPs co-incubated with 
1.6 nM EGF, and NP-EGF (effective EGF concentration 0.2 nM) in serum containing DMEM for 24 h at 
37 °C. Data were collected from at least 11 independent experiments. b. EGFR phosphorylation in HeLa 
after treatment with NP-EGF and pegylated NPs for 2 h and 8 h. All phosphorylation levels are normalized 
to the reference condition: 15 min of incubation with 1.6 nM free EGF (last column). The measured 
phosphorylation levels confirm EGFR activation through nanoconjugated EGF. Figure adapted with 
permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-166. 
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 For 40nm NP-EGF, EGFR overexpressing epidermoid carcinoma (A431) with 
EGFR expression level of 3×106 EGFR/cell was used to study the specific binding and 
uptake of NP-EGF. A431 cells were incubated with the respective NP preparations in 
serum containing DMEM for 24h at 37˚C. The treated cells were harvested and digested 
with aqua regia and dried overnight at 50 °C. The samples were then re-dissolved in 2% 
HCl solution. After an additional 250-1000 fold dilution with 2% HCl, the sample Au 
concentrations were determined through ICP-MS. The results of eleven independent 
experiments are histogrammed in Figure 2.7 a. Under the chosen experimental conditions 
NP-EGF, NP-PEG and mixture of NP-PEG and EGF do not show systematic differences 
in uptake (95% confidence, p < 0.05). Phosphorytion level induced by 40 nm NP-EGF 
were quantified in Figure 2.7 b. In order to eliminate the high autophosphorylation 
background in the EGFR overexpressed cells, HeLa cell with physiological expression 
level of EGF were used (5×104 EGFR / cell). Cells were exposed to 0.05 nM NP-EGF 
(consistent surface EGF concentration = 0.2 nM) or 0.05 nM NP-PEG for 2 h or 8 h 
before collected and lysed. EGFR [pY1068] was used to determine the phosphorylation 
level through ELISA assay. Untreated cells and 1.6 nM EGF treated cells were used as 
background and positive controls, respectively. No phosphorylation was detected after 
cellular exposure to NP-PEG for up to 8 h. While NP-EGF treated cells have a 
significantly higher phosphorylation levels compared with none treated cells and NP-
PEG treated cells. With only 0.2 nM surface EGF concentration, NP-EGF can induce as 
half phosphorylation level as 1.6 nM free EGF treated cells in which the EGF 
concentration is nearly 7 fold higher. Therefore, the EGF functionalized 40 nm NPs 
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retain a distinct character that is evident in the significantly increased phosphorylation 
level. We attribute the observed specificity difference in cellular uptake and 
phosphorylation of 40 nm NP-EGF to the formation of a protein corona under the chosen 
experimental conditions (vide infra). Negative charged 40 nm NP-PEG can absorb the 
positive charged proteins in the culture medium and further utilized it to facilitate binding 
and internalization to cells. Therefore, the binding and uptake of 40 nm NP-EGF and NP-
PEG are comparable. However, due to the dynamic nature of protein corona and the 
length of the PEG2 spacer, the EGF is still biologically available to the cellular surface 
and as a result, NP-EGF is still capable of triggering the signaling cascades.  
 
 
Figure 2.8. Bioactivity and Accessibility of 80 nm NP-EGF.  
a. Cellular uptake of NP-PEG and NP-EGF as determined by ICP-MS. MDA-MB-468 cells were incubated 
with 8 pM NPs for 25min. Fresh DMEM was used for control group (CTRL). N.D. not detectable. b. 
Phosphorylation level induced by NP-EGF. Cells were treated with (left to right) fresh DMEM, 1 nM EGF 
peptide, 8 pM NP-PEG, 8 pM NP-EGF, supernatant from the last wash of NP-EGF for 25 min in the 
incubator before lysed and assayed for phorsphorylated EGFR ELISA measurement. Data were plotted as 
the ratio of different treatment to cells treated with 1 nM EGF and were collected from at least 3 
independent experiments.  
 
  For 80 nm NP-EGF, another EGFR overexpressed cell line, basal-like breast 
cancer (MDA-MB-468), with 1.3×106 EGFR/cell was used due to the lower background 
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scattering from cells which can be beneficial in the microscopic studies in chapter 4 and 
5. MDA-MB-468 cells were incubated with NP-EGF or NP-PEG for 25 min at a 
concentration of 8 pM in DMEM at 37 °C before being harvested and digested with aqua 
regia. Au atom concentration was then measured with ICP-MS and converted to Au NP 
with the same method as for 40 nm Au NPs (Figure 2.8 a). While the Au NP content for 
NP-PEG was negligible with 5 ± 1 NP/cell, for NP-EGF the average Au NP 
concentration was 709 ± 97 NP/cell. The control group without NP incubation showed no 
detectable signal in ICP-MS. The highly selective uptake of NP-EGF confirms that EGF 
remains bioavailable after nanoconjugation and that the NP-cell interactions are mediated 
by EGF. Consistent with EGFR activation by nanoconjugated EGF, robust EGFR 
phosphorylation levels were detected after 25 min of incubation with 8 pM NP-EGF 
(Figure 2.8 b). In fact, the phosphorylation for NP-EGF exceeded that of the same 
concentration of free EGF by approximately 60%. NP-PEG or the supernatant of the last 
wash of NP-EGF cleaning by centrifugation and resuspension showed only background 
phosphorylation levels, confirming that the increase in phosphorylation is EGF dependent 
and a result of nanoconjugation.  
 As described in chapter 1.2, disruption of the intracellular trafficking of the 
EGFR-EGF complex has been shown causally linked to the induced apoptosis. 
Internalization of NP-EGF is thus a crucial step in apoptotic signaling. Therefore, 40 nm 
NP-EGF was used to verify if the Au NPs enter cells and characterize the intracellular 
spatial distribution of the uptaken NPs. HeLa cells were treated with 0.05 nM NP-EGF in 
physiological environment for 4 h before lysosomes were stained with lysotracker 
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(90nM, 15min, red) and Hoechst33342 for nucleus (20min, blue). As it is shown in 
Figure 2.9, after 4 h exposure to NP-EGF, a high concentration of scatters in the 
perinuclear area that colocalized with acidified compartments, as indicated by the 
lysotracker stain, is observed which confirms an enrichment of the uptaken NPs in the 
lysosome through the endosomal pathway. 
 
 
Figure 2.9. Optical Colocalization of NP-EGF and Acidified Cellular Compartments.  
HeLa cells were incubated with EGF-NP for 4h. The dark field image showed the particles (a). Lysosomes 
were stained with fluorescent LysoTracker (b). The cell nucleus was stained with Hoechst 33342 (c). (d) 
overlaid image of three channels. Optical colocalization confirms an enrichment of NPs in perinuclear 
acidified membrane compartments. Similar distributions were obtained for A431 cells. Figure adapted with 
permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-166. 
 
2.4 Conclusion 
 40nm and 80 nm NP-EGF were successfully made and carefully characterized 
before applied to cells. Although for 40 nm NP-EGF with experimental condition, the 
uptake efficiency is comparable for both NP-EGF and NP-PEG, the NP-EGF remain 
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active on the surface of gold and as a result a significant increase in phosphorylation level 
induced by NP-EGF was observed even in HeLa cells with physiological level of EGFR 
expression. As for 80 nm NP-EGF, it has a much higher EGF density on the NP surface. 
Both uptake levels and phosphorylation levels confirm the bioavailability of EGF on the 
NP-EGF surface. 
 40 nm Au NP and 80 nm Au NP have shown different specificity in cellular 
binding and uptake. The difference rises from the following reasons. 1). The cellular 
uptake of Au NPs is size dependent (Chithrani, Ghazani et al. 2006; Zhang, Li et al. 
2009; Wang, Lee et al. 2010; Shan, Ma et al. 2011). It is found that, both experimentally 
and theoretically, the optimal size of uptake is 40-50 nm. The hydrodynamic diameter of 
40 nm Au core NP-PEG is 48.4 nm and together with the assistance of protein corona, it 
is highly possible that 40 nm Au NP-PEG is preferentially uptaken by cells. Therefore, it 
exhibits a similar uptake level as 40 nm NP-EGF. 2). 80nm NP-EGF has higher surface 
density of ligand. According to the ELISA and TEM measurement, there are 4 EGF per 
NP for 40 nm NP-EGF with wide distribution and 124 EGF per NP for 80 nm NP-EGF. 
The higher ligand density may be capable of potentiating the specific uptake and binding 
compared with 80nm NP-PEG. 3). The experimental condition is different. In 40nm Au 
NP uptake experiments, Au NPs and cells were incubated for 24 h. Inevitably, there 
might be large agglomerates fall on the cellular membrane that give a rise in the Au 
background. While in 80nm Au NP uptake experiments, incubation time was shortened to 
25 min within which time window, the monodispersity is maximized for both NP-EGF 
and NP-PEG and help in reducing the Au background due to agglomeration. Thus, 40nm 
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NP-EGF and NP-PEG shows similar cellular uptake and binding due to the optimal size 
while with 80 nm, there is a significant difference between NP-EGF and NP-PEG in both 
cellular uptake and phosphorylation due to the much higher ligand density of NP-EGF. 
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CHAPTER 3 Nanoconjugation Enhanced EGFR Induced Apoptosis 
3.1 EGF Induced Apoptosis 
 Apoptosis, first termed in 1972 by Kerr, Wyllie and Currie (Kerr, Wyllie et al. 
1972), classifies the type of cell death that is characterized by morphological changes 
such as cell shrinking and membrane blebbing (Elmore 2007). This process is highly 
programmed and regulated. It is considered a crucial biological process during an 
organism’s life cycle to remove cells in excess or potentially dangerous. Roughly, 10 
billion cells undergo the apoptosis every day to keep balance with the newly generated 
cells from stem cells in adulthood (Renehan, Booth et al. 2001). Failure in normal rate of 
apoptosis, either increase or inhibition, can cause serious diseases such as AIDS, 
Alzheimers, Parkinsons and autoimmune disorders. In fact, resisting cell death is one of 
the hallmarks of cancer (Hanahan and Weinberg 2011). In general, there are two major 
pathways of apoptosis: the extrinsic death receptor pathway and the intrinsic 
mitochondrial permeability transition pathway (Reed 2000; Elmore 2007). These two 
pathways are not competing events but usually work together to accelerate cell death. 
Caspases, a family of cysteine proteases, are usually involved in both pathways and are 
roughly classified into three groups: upstream initiator caspases (caspase 2, 8, 9, 10), 
downstream effector caspases (caspase 3, 6, 7) and inflammatory caspases (caspase 1, 4, 
5) (Cohen 1997; Salvesen and Dixit 1997; Thornberry and Lazebnik 1998). Both the 
extrinsic and intrinsic pathways (different caspases involved), lead to the execution phase 
where effector caspases are activated to trigger the final stage of apoptosis. Caspase 3 is 
considered to be the most important executioner caspase due to the fact that it can be 
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activated by any of the initiator caspases and is capable of activating the endonuclease 
DNase (Salvesen and Dixit 1997; Porter and Janicke 1999). 
 EGFRs are usually involved in the processes of cell growth, migration and 
differentiation (Hubbard and Till 2000; Schlessinger 2000; Lemmon and Schlessinger 
2010). It has also been known to induce apoptosis in some cell types with overexpressing 
EGFR level treated with high EGF dosage, for example: epidermoid carcinoma (A431) 
and basal-like breast cancer (MDA-MB-468) due to the saturation of the trafficking 
machinery (Gulli, Palmer et al. 1996; Hognason, Chatterjee et al. 2001; Lehto 2001; 
Chen, Huang et al. 2004). The mechanism of the EGF mediated apoptosis remains 
controversial for a long time. Gulli et al showed that the EGF induced apoptosis 
positively relates to the tyrosine kinase activity. Treatment of A431 cells with 10 nM 
EGF showed a 15 folds increase in phosphorylation level and followed by a decline in 
cellular viability. Decreasing the tyrosine kinase phosphorylation with tyrosine kinase 
inhibitor leads to an increase in the cell viability compared with the EGF treated cells 
(Gulli, Palmer et al. 1996). However, this study has not addressed if the apoptosis is 
related to the high EGFR expression level or it is an unusual feature of certain tumor 
cells. Högnason et al. studied the mechanism of this paradoxical apoptotic effect induced 
by EGF. They showed that upregulation of the EGFR expression level leads to apoptosis 
in various cell types. Reducing Ras Signaling potentiates the apoptotic efficacy most 
likely due to the decreased Akt activation as a consequence of blocking Ras down-stream 
effects (Hognason, Chatterjee et al. 2001). Etk/Bmx, a member of tyrosine kinases in Tec 
family, was also found involved in the EGF-induced apoptosis of MDA-MB-468 cells by 
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Chen et al. Overexpressed Etk is associated with Stat1 activation and augment EGF 
induced apoptosis in MDA-MB-468 cells (Chen, Huang et al. 2004). Although the 
underlying molecular mechanism is not fully illustrated, there is now mounting evidence 
that the location of EGFR plays a role in apoptosis mediation (Lehto 2001). Rush et al 
have studied the mechanism of EGF induced apoptosis in MDA-MB-468 cells and found 
that overexpression of EGFR leads to the accumulation of the phosphorylated EGFR on 
the limiting membrane of the early endosomes and this accumulation can initiate the EGF 
induced apoptosis (Rush, Quinalty et al. 2012). Interestingly, in their study perturbation 
of EGFR trafficking is shown to sufficiently initiate apoptosis in HeLa cells (with 
physiological level of EGFR expression).  
 The general understanding is that disruption of the EGFR-EGF trafficking 
through the endosomal pathway is potentially capable of inducing apoptosis. So the 
question is with the ability of interfering ligand intracellular trafficking, can 
nanoconjugation influence the EGF induced apoptosis? Therefore, in the following 
section, we describe a careful study of nanoconjugated EGF induced apoptosis, in terms 
of the caspase 3 activity.  
3.2 Apoptotic Efficacy of Nanoconjugated EGF 
 Caspases play a central role in regulating apoptosis in mammalian cells and 
caspase 3, in particular, is frequently used to quantify apoptosis (Salvesen and Dixit 
1997; Thornberry and Lazebnik 1998; Porter and Janicke 1999). Control experiments to 
validate that under our experimental conditions increased caspase 3 levels were indeed 
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caused by apoptosis were first conducted by checking the signature morphological 
changes of apoptotic cells.  
 A431 cells were incubated with 40 nm NP-EGF (60 pM) and free EGF (33 nM) 
as positive control for 72 h before fixing and staining with apoptotic markers. Nuclei 
condensation, morphological change and phosphatidylserine (PS) translocation were 
checked with darkfield microscope and widefield fluorescence microscope. Compared to 
the nontreated control group, obvious cell nuclei contraction (Fig. 3.1), characteristic 
changes in the cell morphology (Fig. 3.2), and phosphatidylserine translocation in cells 
with intact plasma membrane (Fig. 3.3) were observed for NP-EGF treated cells similar 
to the positive control: 33 nm EGF treated groups. After 72 h exposure to NP-EGF, the 
nucleus cross section decreased to about 65% of the nontreated group accompanied with 
lower cell density and round-up morphology (Fig. 3.2). Annexin V was used to stain the 
translocated PS presented in apoptotic cells and propidium iodide (PI) was used to stain 
dead cells due to the increased permeability of dead cell membrane. The NP-EGF treated 
cells showed a high population of Annexin V positive cells with moderate staining of PI 
compared with 33 nM EGF treated group. Therefore, it is confirmed that the process that 
cells undergo after exposure to NP-EGF is apoptosis as signature morphological changes 
were observed.  
 In the following sections, caspase 3 activity was chosen as a metric to quantify 
apoptosis in the different experimental conditions (Häcker 2000; Hengartner 2000; 
Saraste and Pulkki 2000; Toné, Sugimoto et al. 2007). 
  
36 
 
 
Figure 3.1. Nucleus Condensation.  
Nucleus size and morphology was evaluated after staining with Hoechst 33342 muclear fluorescent stain. 
A431 cells exposed to 33nM EGF and P3 contain distinctly smaller nuclei. relative nucleus cross-section 
was determined as relative to the blank control. Nuclear condensation is another morphological indication 
of apoptosis. Figure adapted with permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-166. 
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Figure 3.2. Cellular Morphological Changes.  
Darkfield images of A431 cells cultured for 72h in serum containing DMEM (top row), in medium with 
33nM EGF (middle row) and in medium containing NP-EGF (bottom row). Rounding-up of cells (arrow) is 
observed in 33nm EGF and NP-EGF treated cells but not in the controls. Rounding-up is a morphological 
indication of apoptosis. Figure adapted with permission from Wu L. et al., Biomater. Sci., 2014, 2, 156-
166. 
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Figure 3.3. Phosphatidylserine (PS) Translocation/Plasma Membrane Integrity Assay.  
A431 control cells and cells exposed to EGF and NP-EGF for 72h were harvested and stained with 
fluorescent propidium iodide (PI) and Annexin V at room temperature for 25min and imaged after washing 
two times through centrifugation. DNA staining through PI is indicative of ruptured membranes in dead 
cells, whereas Annexin V staining indicates PS translocation into the outer membrane leaflet, which 
indicates apoptosis. The overall low PI intensity and strong Annexin V labeling intensity in cells treated 
with EGF or NP-EGF is characteristic of apoptosis. Figure adapted with permission from Wu L. et al., 
Biomater. Sci., 2014, 2, 156-166. 
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3.2.1 Apoptosis Induced by 40 nm NP-EGF 
 A431 cells, with overexpression of EGFR were chosen for this systematic 
comparison since it has been shown before that free EGF in nanomolar range is capable 
of inducing apoptosis in this cell line. Cells were plated in 12-well dishes. After 24h, the 
growth medium was replaced by fresh medium containing different treatment: 1). free 
EGF at concentrations of 1.6 or 33 nM, 2). a mixture of 1.6 nM free EGF solution with 
NP-PEG, or 3.) 60 pM nanoconjugated EGF. NP-PEG and supernatant from the last wash 
of NP-EGF in the purification step after crosslinking reactions were also included in this 
study to determine the background apoptosis levels from NPs and residual free EGF or 
copper catalyst through the NP-EGF preparation. Cells were further incubated for up to 
72 h. Every 24 h, cells were harvested and lysed. The apoptotic activity was then 
measured for different treatments by assaying the caspase 3 activity. The assay is based 
on spectrophotometric detection of the rhodamine 110 (R110) which can be cleaved from 
the substrate Z-DEVD-R110 by caspase-3.  
 Figure 3.4 a plots the relative average caspase 3 activity (± standard deviation) of 
A431 cells with different treatments. Caspase-3 activities were checked every 24 h and 
data was normalized with the caspase 3 activity of the A431 blank control obtained at the 
respective incubation times. The A431 controls did not exhibit significant change (p < 
0.05) in caspase 3 activity as a function of time, as was the case for the NP-PEG as well. 
Therefore, the apoptotic effect of Au NPs by themselves was negligible under the chosen 
experimental conditions. In the cells treated with 1.6 nM EGF, although the average 
caspase-3 activities were higher (~120 %) than controls, the data was broadly spread and 
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a statistically significant increase in caspase 3 activity only observed after 72 h of 
incubation. However, if the EGF concentration was increased to 33 nM, a highly 
significant (p < 0.01) increase in caspase 3 activity to ~132 % was already obtained after 
24 h and 48 h exposure, which further increases to ~178 % after 72 h. These observations 
were in very good agreement with previous studies that have reported apoptosis in A431 
in response to free EGF concentrations in the low tens of nM range. The simple mixture 
of EGF and NP-PEG solutions (EGF not covalently attached) resulted in a weak 
synergistic increase in apoptosis. It yielded a significant increase in the caspase 3 activity 
to ~133 % after 48 h incubation, which slightly decreased to ~125 % after 72 h. Although 
the measured caspase 3 increase in this treatment has a higher significance than observed 
for 1.6 nM EGF alone, the magnitudes of average caspase 3 levels were similar. The data, 
therefore, did not support the presence of a strong synergistic effect between simple non-
covalent mixture of EGF and NP-PEG. This situation changes, however, upon covalent 
attachment of EGF to Au NPs. A highly significant increase in caspase 3 activity to ~156 
% was obtained for the NP-EGF treated cells after 48 h exposure. The caspase 3 activity 
in the presence of NP-EGF further increased to ~185 % after 72 h. Despite the low 
effective EGF concentration of only ~0.2 nM (NP concentration: 60 nM), NP-EGF 
induced a higher average apoptosis level than free EGF at a concentration of 33 nM after 
48 h. After 72 h, cells incubated with NP-EGF and 33 nM free EGF still show 
comparable levels of apoptosis. According to these data, nanoconjugation strengthens the 
apoptotic efficacy, measured as caspase 3 activity, of EGF in the EGFR overexpressing 
cell line A431 by approximately two orders of magnitude. 
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Figure 3.4. Relative Caspase 3 Activities Induced by 40nm NP-EGF.  
a. Relative caspase-3 activity of A431 cells after 24h, 48h, and 72h of incubation in serum containing 
DMEM at 37˚C with (left to right): blank controls; pegylated NPs (P1, 0.06 nM); free EGF (1.6 nM); 
pegylated NPs (0.06 nM) with 1.6 nM free EGF (P2); nanoconjugated EGF (P3, 0.06 nM); free EGF 
(33nM); P3 supernatant. b. Relative caspase-3 activity in HeLa cells after 24h, 48h, and 72h of incubation 
in serum containing DMEM at 37˚C with (left to right): blank controls; P1, free EGF (1.6 nM); P2; P3. All 
caspase-3 activities are normalized to controls after 24h. Measured activities that were significantly (p < 
0.05) higher than controls are marked by *, highly significant differences (p < 0.01) are marked by **. Data 
were collected from at least 6 independent experiments. Figure adapted with permission from Wu L. et al., 
Biomater. Sci., 2014, 2, 156-166. 
 
 In a second step, whether nanoconjugation is also capable of inducing apoptosis 
in cells with physiological level of EGFR expression was investigated. Hela cells were 
chosen to use since they do not undergo apoptosis in response to exposure of high dose of 
free ligand. The experimental details were otherwise identical to the studies for A431 
described above. Relative caspase 3 activates as a function of time were plotted in Fig. 
3.4 b. The data did not indicate NP-PEG or free EGF-induced apoptosis in HeLa. 
Importantly, the non-covalent mixture of free EGF and NP-PEG did also not result in 
enhanced apoptosis. While free EGF and simple mixture of EGF and NP-PEG did not 
suffice to induce apoptosis in HeLa, nanoconjugation changes the apoptotic efficacy of 
EGF and induced measurable apoptosis levels. For NP-EGF a highly significant increase 
  
42 
in caspase 3 activity to approximately 117% was obtained after 24 h, which further 
increases to ~122 % after 48 h and to ~134 % after 72 h.  
 The observation of a robust apoptosis increase even in HeLa cells demonstrated 
that the effect of EGF nanoconjugation was not merely limited to enhancing EGF-
induced apoptosis in EGFR overexpressing cells. Instead, the ability to induce apoptosis 
in cells that did not normally experience apoptosis implies that nanoconjugation 
modulates fundamental cellular regulation processes associated with apoptosis. 
 Above measurement was based on an ensemble level of cells as a function of 
time. Additional insights can be obtained by characterizing the impact of EGF 
conjugation at the single cell level as well as a further validation of the caspase 3 
measurement. To this end, after incubation with NP-EGF for 24-72 h, A431 cells were 
stained with annexin V and propidium iodide (PI). Annexin V binds specifically to 
phosphatidylserine (PS) so that fluorescently labelled annexin V is commonly used to 
detect PS translocation from the inner to the outer leaflet, which is a characteristic event 
in apoptosis (Hengartner 2000). The fluorescence of PI increases when intercalated with 
DNA, and thus PI staining indicates ruptured plasma membranes in dead cells. 
 After 24 h of incubation no staining with either annexin V or PI was observed 
(Fig. 3.5a), but the situation changed after 48 h (Fig. 3.5b) when up to 20% of the cells 
showed strong staining with annexin V. A large fraction of the annexin V positive cells 
were PI negative, which was characteristic of early apoptosis. The number of annexin V 
labelled cells further increase after 72 h (Fig. 3.5c). This observation is consistent with 
the bulk measurement of caspase 3 activity. Although the overwhelming majority of the 
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cells in the ensemble was annexin V positive by 72 h, not all of the cells stained with 
annexin V. Overall, Fig. 3.5 a-c reveals a significant level of cell-to-cell variability in the 
outcome of NP-EGF exposure. This finding was consistent with previous studies that 
apoptosis in general to be an intrinsically heterogeneous process even in genetically 
identical cell populations (Nicoletti, Migliorati et al. 1991). 
 
 
Figure 3.5. Analysis of Apoptosis in Single Cell Level Induced by 40nm NP-EGF.  
Analysis of apoptosis at the single cell level. Co-staining of A431 cells with fluorescently labelled annexin 
V (green) and propidium iodide, PI, (red) after (a) 24 h, (b) 48 h, and (c) 72 h of incubation with P3. The 
scattering images of the cells are included in black-and-white. Figure adapted with permission from Wu L. 
et al., Biomater. Sci., 2014, 2, 156-166. 
 
3.2.2 Apoptosis Induced by 80 nm NP-EGF 
 Basal-like breast cancer cells (MDA-MB-468) with overexpression level of 
EGFR were used to study the apoptosis level induced by 80 nm NP-EGF due to the lower 
scattering background under the darkfield microscope compared with A431 which is 
beneficial in the following investigation of NP-EGF intracellular trafficking. 
 To maximize the monodispersity of 80 nm NP-EGF, lower concentration (60 pM 
for 40 nm NP-EGF vs. 8 pM for 80 nm NP-EGF) and shorter exposure time (24 h for 40 
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nm NP-EGF at least vs. 4 h for 80 nm NP-EGF) were used as determined by the stability 
test of 80 nm NP-EGF in chapter 2. MDA-MB-468 cells (70% confluency) were 
incubated with 8 pM NP-EGF for 4 h at 37 °C in DMEM. After that, the NP-EGF 
suspension was removed and fresh complete growth medium was added to the MDA-
MB-468 cells. The cells were further incubated for 20 h at 37 °C before MTT and 
caspase 3 assays were performed to quantify cell viability and apoptosis, respectively. 
Figure 3.6a shows the cell viability after different treatments. Only NP-EGF treatment 
resulted in a measurable reduction of the cell viability by 18% (p<0.05); free EGF or NP-
PEG controls induced no significant change. The measured relative caspase 3 activities 
for the different experimental conditions are summarized in Figure 3.6b. Although, 
reduced cell viability and increased caspase 3 activity is observed in 33 nM free EGF 24 
h continuously treated cells (Rush, Quinalty et al. 2012), under the chosen experimental 
condition of 4 h exposure time, even high doses of free EGF (33 nM) did not induce 
apoptosis in MDA-MB-468 cells. However, 8 pM NP-EGF corresponding to an effective 
EGF concentration of 1 nM was sufficient to induce a significant increase by 50% 
(p<0.01) over the control (no treatment) in caspase 3 activity. Other controls, such as 8 
pM NP-PEG and the supernatant of the last wash of NP-EGF, did not result in any 
increase in caspase 3 activity.  
 However, since NP-PEG exhibits a much lower cellular uptake under the 
apoptosis experimental condition than NP-EGF (Figure 2.10 a), a comparison of the 
caspase 3 levels induced by NP-EGF and NP-PEG were insufficient to rule out the 
possibility that the observed apoptosis is a consequence of increased intracellular Au NP  
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Figure 3.6. Relative Caspase 3 Activities Induced by 80nm NP-EGF.  
a. MTT cell viability assay. Cells were treated with 1) No treatment 2) 33 nM EGF 3) 8 pM NP-PEG and 4) 
8 pM NP-EGF for 4 h at 37 °C and chased in fresh growth medium for another 20 h. MTT assay were 
applied to measure the cell viability. Data were plotted as the ratio of the treated cells to the non-treated 
control group in DMEM. b. Relative caspase-3 activity change. MDA-MB-468 cells were incubated (left to 
right) with 33 nM EGF peptide, 8 pM NP-PEG, 33 nM membrane wrapped Au nanoparticles (MW-NP), 8 
pM NP-EGF, 8 pM NP-EGF with presence of 1 µM AG1478, 1 µM AG1478 and supernatant from the last 
wash of NP-EGF by centrifugation. The cells were incubated for 4 h and chased in fresh growth medium 
for 20 h. Data were plotted as the increased percentage of caspase-3 activity of control cells treated with 
fresh DMEM and were collected from 6 independent experiments. c. Relative cellular uptake of NPs with 4 
h incubation time. Cells were incubated with 8 pM NP-PEG, 33 nM MW-NP, and 8 pM NP-EGF for 4h. 
The MW-NPs achieved significant non-specific uptake after 4 h incubation with cells at more than 2.5 fold 
higher compared with NP-EGF NP-EGF.  
 
concentration. To address this potential problem, lipid membrane wrapped NPs (MW-
NP; initial membrane composition: 2% phosphatidylserine (PS), 58% 
dipalmitoylphosphatidylcholine (DPPC), 40% cholesterol) were used as an additional 
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control. Chloroform solution of 20 µL 1mM PS, 55 µL 10 mM DPPC, 40 µL 10 mM 
cholesterol was mixed and dried with rotary evaporation to form the lipid dry layer and 
further dehydrated overnight under vacuum. 1mL 20 mM HEPES buffer was added to the 
lipid and sonicated for 2-4min to form liposomes. 24 µL 2mg/mL octadecanethiol in 
ethanol was then added to the liposomes and incubated for 1 h at room temperature. 
80nm citrate protected Au NP was then added to the mixture and further incubated 
overnight at room temperature. The hydrodynamic diameter of the MW-NP is 90.2 ± 0.9 
nm. The membrane wrapped NPs remained stable even when incubated with cells in 
DMEM in the tens of nanomolar concentration range where non-specific binding and 
uptake resulted in elevated intracellular NP concentrations (Figure 3.6c). As it is shown 
in Figure3.6b, even for Au MW-NP treated cells, whose intracellular Au concentration 
exceeded that of NP-EGF treated cells by 150%, no significant increase in apoptosis was 
detected.  
 Previous studies have shown that EGFR signaling is crucial in triggering EGF 
induced apoptosis. Therefore, the importance of EGFR signaling was also tested in NP-
EGF triggered apoptosis by blocking the EGFR phosphorylation with AG1478. AG1478 
is an EGFR specific tyrosine kinase inhibitor which is commonly used to inhibit the 
tyrosine kinase but keep the internalization of EGF-EGFR complex unaffected. Figure 
3.6b shows that presence of EGFR kinase inhibitor AG1478 can significantly decrease 
the caspase 3 activity induce by NP-EGF which indicates a vital role of EGFR signaling 
in NP-EGF triggered apoptosis. 
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 Altogether, the data verified that the observed increase in apoptosis upon 
administration of NP-EGF results from the nanoconjugation of EGF and the ability of 
inducing EGFR signaling. 
3.3 Conclusion 
 In this chapter apoptosis levels induced by 40 nm and 80 nm NP-EGF were 
measured in terms of caspase 3 activity. Data showed that nanoconjugation enhances 
apoptotic efficacy in EGFR overexpressed cell lines such as A431 and MDA-MB-468 
cells and is capable of inducing apoptosis in tumor cells with physiological EGFR 
expression level like in HeLa cells. Moreover, the ability of inducing apoptosis of 80 nm 
NP-EGF is astonishing. Under the chosen experimental condition where no apoptosis 
activities were introduced by very high EGF treatment (33 nM), a significant increase in 
apoptosis activities was observed in MDA-MB-468 cells treated with 80 nm NP-EGF. 
Therefore, a careful study of intracellular trafficking and signalling induced by 80 nm 
NP-EGF was conducted in the following chapters. 
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CHAPTER 4 NP-EGF Endosomal Accumulation and Signaling 
4.1 EGFR Trafficking Pathway and Signaling 
 According to the textbook model of EGFR signaling activation (Schlessinger 
2000; Schlessinger 2002), the binding of EGF to the extracellular domain of EGFR 
induces conformational changes that result in the dimerization of receptors. The 
dimerization facilitates a cross-phosphorylation of the tyrosine kinase domains and 
initiates downstream signaling events. In cells with receptor expression at the 
physiological level, EGF binding to EGFR triggers endocytosis through a clathrin-
dependent pathway, whereas in EGFR overexpressing cells, clathrin-independent 
pathways have been observed especially in the presence of high EGF concentrations 
(Sigismund, Argenzio et al. 2008; Sorkin and Goh 2009). Importantly, the activated 
EGFRs remain dimerized with the phosphorylated tyrosine kinase domain exposed in the 
cytoplasm after internalization into early endosomes (Sorkin and Goh 2009; Tomas, 
Futter et al. 2014; Villaseñor, Nonaka et al. 2015). In this fashion, the receptor continues 
to signal during intracellular events until it is dephosphorylated by a protein tyrosine 
phosphatase (Tiganis 2002; Tomas, Futter et al. 2014), the ligand is removed from the 
endosome (Burke, Schooler et al. 2001), or the EGFR* (the star marks phosphorylation) 
containing endosome is encapsulated in a multivesicular body (Wang, Pennock et al. 
2002). The accompanying removal of the phosphorylated receptor tail from the 
cytoplasm renders the phosphorylated EGFR inaccessible and results in signal 
termination.  
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 Although long controversial (Brankatschk, Wichert et al. 2012; Sousa, Lax et al. 
2012), there is now mounting evidence that endosomes represent signaling platforms for 
transmembrane receptors and that the signal from receptors in endosomes can differ from 
those localized at the plasma membrane (Murphy, Padilla et al. 2009; Rush, Quinalty et 
al. 2012; Irannejad, Tomshine et al. 2013; Villaseñor, Nonaka et al. 2015). The picture 
that has emerged recently is that the outcome of the endosomal EGFR signaling 
sensitively depends on the temporo-spatial distribution of the EGFR* containing 
endosomes and the number and nature of receptors embedded in the endosomes. While 
the former influences and regulates the interplay of the receptor with intracellular effector 
molecules (Ceresa 2011), the latter modulates signaling through cooperative interactions 
facilitated by spatial co-localization of different receptors (Villaseñor, Nonaka et al. 
2015). Due to these spatial aspects of the signaling regulation, the disruption of the 
trafficking of EGF-EGFR* could lead to dramatic changes in the outcome (Mosesson, 
Mills et al. 2008). For instance, saturation of the cellular trafficking machinery in EGFR 
overexpressing epidermoid carcinoma (A431) or basal-like breast cancer (MDA-MB-
468) cells after exposure to high concentrations of EGF was found to trigger apoptosis 
due to an accumulation of EGF-EGFR* in early endosomes (Hyatt and Ceresa 2008; 
Rush, Quinalty et al. 2012). It has been shown in the last chapter that conjugation of EGF 
to 40 nm and 80 nm Au NPs results in EGF mediated apoptosis at effective ligand 
concentrations that are much lower than what is required for the free EGF to trigger 
apoptosis (Wu, Yu et al. 2014). However, the mechanism underlying this observation 
remains unclear. Due to the temporo-spatial regulation nature of EGFR signaling, it is 
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intuitive to assume that the covalent attachment of a ligand to a NP affects its endocytosis 
and subsequent trafficking. Consequently, the temporo-spatial regulation of endosomal 
EGFR signaling makes the signaling outcome susceptible to intervention via 
nanoconjugation. The hypothesis of the observed apoptosis enhancing ability of 
nanoconjugation is that it can prolong the dwelling time of NP-EGF-EGFR* complex in 
the early endosomes. Therefore, in this chapter, the impact of EGF nanoconjugation on 
endosomal EGF-EGFR* trafficking was studied to prove the hypothesis.  
 The traditional way of studying NPs intracellular trafficking is based on 
microscopy where the intracellular organelles of interest are labeled and visualized. By 
searching for the correlation between NPs and labeled organelles, temporo-spatial 
information of NPs trafficking can be provided. However, with this method, it is 
impossible to generate data based on a large population of cells. Due to the heterogeneity 
of cancer cells, it is important to study the behaviors on an ensemble level to eliminate 
subjective bias. Another challenge for the analysis of intracellular signaling is the need 
for distinguishing signals that emanate from the plasma membrane from those that are 
associated with intracellular endosomes since the latter is the one responsible for 
apoptotic signaling. To accomplish these goals, a two-pronged approach is developed and 
applied in this chapter. 80 nm Au NPs were utilized both as a “load” to facilitate a 
density-based separation of NP-EGF containing endosomes as well as bright optical 
probes to map the temporo-spatial distribution of the nanoconjugated EGF and 
characterize NP-EGF interaction with the cellular trafficking machinery. Au NPs are 
uniquely suited for this study as they can be synthesized with narrow size distribution 
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over a broad size range,(Daniel and Astruc 2004; Ziegler and Eychmuller 2011; Zhao, Li 
et al. 2013) and the surface properties of Au NPs can be well controlled through 
established Au-thiol chemistries (Sapsford, Algar et al. 2013). Furthermore, Au NPs have 
been found to be compatible with diverse biomedical applications(Shukla, Bansal et al. 
2005; Murphy, Gole et al. 2008; Alkilany and Murphy 2010; Lee and Lee 2010; Dykman 
and Khlebtsov 2012; Lee, Chen et al. 2015) and they provide large optical scattering 
cross-sections (Murphy, Gole et al. 2008; Dreaden, Alkilany et al. 2012) that make them 
useful probes in darkfield microscopy.  
 In this chapter, a novel endosomal sorting technique based on the density shift of 
the Au containing endosomes was developed and applied to characterize the relative 
contribution from nanoconjugated EGF in early and late endosomes as a function of time 
in an entire cell population. An unambiguous comparison of NP-EGF and free EGF 
trafficking under the same experimental conditions was conducted with traditional 
colocalization microscopy.  
4.2 Endocytosis Pathway of NP-EGF 
 Endocytosis is an integral part of signaling regulation. Cells with receptor 
expression at physiological levels exposed to environments treated with native EGF 
concentrations (<1-2ng/mL) internalize the EGF-EGFR complex via a fast clathrin-
mediated endocytosis process (Chinkers, McKanna et al. 1979; Haigler, McKanna et al. 
1979; Yamazaki, Zaal et al. 2002; Orth, Krueger et al. 2006; Sigismund, Argenzio et al. 
2008). Alternatively, slower clathrin-independent uptake mechanisms have also been 
observed under different experimental conditions with higher EGF concentration for 
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EGFR overexpressed cell lines (Aoki, Nomura et al. 1999; Coller and Paulnock 2001; 
Hambleton, Steinberg et al. 2007). In case of EGFR overexpressed cell lines such as 
A431, caveolae mediated endocytosis and micropinocytosis are proposed as the 
mechanisms of EGFR internalization in response to high dosage EGF stimulation (West, 
Bretscher et al. 1989; Anderson 1998). Studies have shown that the signaling and 
internalization speed of EGFRs localized to caveolae is different (Engelman, Chu et al. 
1998; Mineo, Gill et al. 1999; Hyatt and Ceresa 2008; Sigismund, Argenzio et al. 2008) 
and given the potential role of the temporo-spatial distribution of the activated receptor in 
modulating endosomal signaling, a correct interpretation of the observed apoptosis 
requires the identification of the internalization mechanism. Also, Wang et al has 
reported that the apoptotic effect was associated with a clathrin-independent endocytosis 
induced by multivalent presentation of the human transferrin on NPs surface (Wang, Tian 
et al. 2010). It is necessary to check if the NP-EGF employs a clathrin-independent 
pathway to induce apoptosis, as was observed in the transferrin functionalized NPs. To 
this end, well-established pharmacological inhibitors were used to block specific 
endocytosis pathways. Amantadine is known to block the budding of clathrin-coated pits 
(Perry, Daugherty et al. 1999) and monodansyl cadaverine (MDC) is capable of 
inhibiting transamidase activity and clathrin-coated pit formation(Coller and Paulnock 
2001). Thus, these two inhibitors were used both to block clathrin-mediated endocytosis. 
Nystatin can deplete cholesterol in cell membrane and disrupts lipid raft (Hambleton, 
Steinberg et al. 2007) while genistein can block the phosphorylation of caveolin (Aoki, 
Nomura et al. 1999). These two chemicals were applied to inhibit caveolae (lipid raft)- 
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mediated endocytosis. Colchicine can depolymererize microtubules to block the 
micropinocytosis. To ensure that only intracellular Au NPs (uptaken NP-EGF) were 
considered in our comparison of the different inhibitors, an aqueous etchant solution of 
I2/KI was used before fixation of cells to remove all Au NPs bound to the surface and 
leave the intracellular Au NPs intact. This etchant at low concentration is of low toxicity 
and is capable of removing most of the surface bound gold (Cho, Xie et al. 2009). 
Together with darkfield microscopy or ICP-MS, qualitative and quantitative 
measurement of intracellular Au NPs concentration after inhibition of specific 
endocytosis pathway can be achieved and information of endocytosis pathway can be 
provided.  
 
 Function Experimental Dosage 
Amantadine 
block the budding of clathrin-coated pits 
5 mM, 30min 
MDC inhibiting transamidase activity and clathrin-
coated pit formation 
200 μM, 20min 
Nystatin 
disrupts lipid raft 
50 μg/mL, 15min 
Genistein 
block caveolin phosphorylation 
200 μM, 60min 
Colchicine 
depolymererize microtubules 
10 μg/mL, 30min 
Table 4.1. Pharmaceutical Inhibitors. 
 
 An overview of the applied pharmacological inhibitors, the affected uptake 
mechanisms and the experimental details are summarized in Table 4.1. In general, MDA-
MB-468 cells were treated with different pharmacological inhibitors in growth medium 
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to reach the desired blocking of the specific pathway before further exposure to 8 pM 
NP-EGF for 20 min at 37 °C in the presence of inhibitors. 1 mL of the I2/KI aqueous 
solution (0.34 mM I2, 2.04 mM KI) was then added to the culture flask and incubated at 
room temperature for 3 min and washed 3 times with HBSS buffer before the samples 
were fixed and analyzed with darkfield microscope or ICP-MS. 
 
 
Figure 4.1. Pharmacological Inhibition Study of Endocytosis Pathway.  
Darkfield images of MDA-MB-468 cells pre-treated with different inhibitors of clathrin (amantadine, 
mondansyl cadaverine), caveolae (genistein, nystatin) and pinocytosis (colchicine) dependent endocytosis 
after incubation with 8 pM NP-EGF for 20 min (ctrl = no treatment). Surface bound NPs were removed by 
I2/KI etch prior to imaging. 
 
 The darkfield images in Figure 4.1 show that after 20 min exposure to 8 pM NP-
EGF, nontreated MDA-MB-468 cells internalized significant amount of Au NPs. 
Colchicine, nystatin and genistein treated cells showed no obvious decrease of Au NP 
  
55 
  
 
 
Figure 4.2. Validation of Pharmacological Inhibitors.  
Inhibition of caveolae mediated endocytosis with genistein and nystatin. MDA-MB-468 cells were 
pretreated with 200 µM genistein for 60 min or 50 µg/mL nystatin for 15min. Then 5 µg/mL cholera toxin 
B Alexa 488 conjugate (CTB) was incubated with cells for 20 min with presence of inhibitors. Cells were 
washed twice with HBSS buffer and fixed with 4% PFA before imaged with confocal microscope. Left to 
right: Confocal images of CTB, DIC images of cells, overlay images of CTB and cells, enlarged images of 
the red squared area. Genistein (top) and nystatin (middle) treated cells showed a decrease uptake of CTB 
compared to cells without inhibitor treatment which showed a significant higher uptake (bottom). Scale bar 
10 µm. 
 
 
cellular uptake. But amantadine and MDC achieved an obvious reduction of NP-EGF 
uptake. Since pharmaceutical inhibitors are known unspecific, positive controls for the 
nystatin and genistein that didn’t show the blocking of endocytosis were conducted to 
validate the inhibiting ability of the caveolae (lipid raft)-mediated endocytosis (Figure 
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4.2). Cholera toxin B Alexa 488 conjugate (CTB) which is known to enter cells through 
the caveolae (lipid raft)-mediated endocytosis, was employed for this purpose. Figure 4.2 
shows that genistein and nystatin under the chosen experimental condition can 
successfully decrease the uptake of CTB (5 µg/mL) compared to cells without prior 
inhibitor treatment. For two selected inhibitors (amantadine and nystatin), intracellular 
Au concentrations were quantified by ICP-MS to validate the results for the optical 
darkfield imaging studies (Figure 4.3). Amantadine, but not nystatin, blocked the 
nanoparticle uptake by around 65%, confirming that under the chosen experimental 
conditions, a fast clathrin-dependent endocytosis dominates the internalization of NP-
EGF. 
 
 
Figure 4.3. Relative Cellular Uptake with Pharmacological Inhibition.  
Relative cellular uptake of NP-EGF with two representative inhibitor: amantadine and nystatin after 
incubation with 8 pM NP-EGF for 20min and I2/KI etching. 
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4.3 Isolation and Characterization of NP Containing Endosomes 
 The impact of EGF nanoconjugation on the spatial EGFR signaling and its role in 
apoptosis was elucidated by characterizing the distribution of NP-EGF on early and late 
endosomes as a function of time using the endosome isolation technique outlined in 
Figure 4.4. A traditional commonly used method to study the intracellular trafficking of 
NPs is based on microscopy. It is well-established and very intuitive. However, one of 
the disadvantages of this microscopic method is the limitation in sample size, which is 
good to obtain data in a single cell level but becomes weak when a large quantity of cells 
are needed. The outlined approach in Figure 4.4 takes advantage of the heavier weight of 
NP-EGF containing endosomes, due to the presence of high density of Au (19.3 g/cm3), 
to separate them from NP-free endosomes by centrifugation at low g-forces.(Tjelle, 
Brech et al. 1996) A successful isolation of NP-containing endosomes makes them 
amenable to characterization through standard immunoassays such as ELISA. Therefore, 
this method is capable of quantifying the average accumulation of NP-EGF in a large 
population of cells (millions). As is discussed above, endosomal signaling of EGFR plays 
a vital role in determining the ultimate biological outcome of EGF stimulation. Another 
challenge of investigating the EGFR endosomal signaling in EGFR overexpressed cell 
lines is the inability of separating the endosomal phosphorylation signals from the 
membrane localized EGFR*. This issue is well solved by combining the endosomal 
sorting method with the etching technique where surface bound NP-EGF is removed by 
mild etchant I2/KI to avoid the collection of surface EGFR*. 
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Figure 4.4. Scheme of Endosomal Sorting Experiment.  
Schematics of sample preparation (top row) and NP distribution (bottom row). MDA-MB-468 cells were 
incubated with 8 pM NP-EGF for 2 h at 4 °C and then chased in fresh growth medium at 37 °C for the 
specified time before the cells were harvested. To measure phosphorylation of endosomal EGFR, surface 
NP-EGF were etched away with I2/KI prior to cell harvesting. 40 strokes through a 23 gauge syringe were 
applied to the collected cell suspension to break the cellular membrane but retain the endosomal membrane. 
The Au NP containing endosomes were then collected by centrifugation and assayed with ELISA of 
different markers. 
 
 8 pM NP-EGF was incubated with MDA-MB-468 cells at 4 °C for 2 h in DMEM 
to maximize the binding. Then, the colloidal solution was removed, cells were washed 
with ice-cold 1X PBS twice and endocytosis was initiated by increasing the temperature 
to 37 °C. After further incubation for another 5 - 95 min at 37 °C in 5% CO2, cells were 
subsequently washed twice with ice-cold HBSS buffer and homogenization buffer (0.25 
M sucrose, 10 mM triethanolamine, 10 mM acetic acid, 1 mM EDTA, 2 mM Na3VO4, 1 
mM PMFS, 1:20 protease inhibitor cocktail, pH 7.8) before the cells were harvested in 
1mL homogenization buffer with a scraper. Mild shear force was applied to the cell 
suspension to break up the cell membrane but keep the endosomal membrane intact 
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through 40 strokes with a 23 gauge syringe. This process was checked by light 
microscopy. After homogenization, the Au NP containing endosomal fractions were 
pelleted at 800 g for 10 min and washed with centrifugation in ice-cold 1X PBS. The 
samples were then divided into three parts. The early endosome antigen 1 (EEA1) and the 
Ras-related protein Rab7a were used as biomarkers for the early and late endosome 
(Feng, Press et al. 1995; Mu, Callaghan et al. 1995; Vanlandingham and Ceresa 2009). 
The EEA1 and Rab7a levels of the isolated endosomes were measured by ELISA as a 
function of time. Concentration of phosphatidylcholine (PC), a major membrane 
component, was also quantified by enzyme-coupled colorimetric reaction as an internal 
standard for the relative amount of isolated endosomes (Leventis and Grinstein 2010). All 
EEA1 and Rab7a intensities were normalized by the measured PC concentration.  
 
 
Figure 4.5. Endosomal Accumulation and Signaling of NP-EGF.  
a. Relative NP-EGF levels in early endosomes (EEA1, olive) and late endosomes (Rab7a, orange) at 
different time points. Data was normalized with phosphatidylcholine as a reference of the total amount of 
isolated endosomes and was plotted as the relative change to the lowest data point. 6 independent 
experiments were included in the plot. Error bars indicate standard deviations. b. Control of nonspecific 
collection of early endosomes. 80 nm NP-EGF was incubated with non-treated cell lysate for 30 min at 
room temperature before endosomal collecting with 800 g centrifugation. EEA1 level was determined with 
ELISA. Ratio of EEA1 concentration and PC concentration was calculated. Data were plotted as the ratio 
of control to cells chased for 80min at 37 °C after 2 h incubation with NP-EGF at 4 °C. 
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 Figure 4.5a plots the relative change in average EEA1 and Rab7a intensity as a 
function of time between t = 5 - 95 min.  Although the measured EEA1 and Rab7a levels 
from at least six independent experiments show a broad spread, the averages follow clear 
trends. After an initial delay related to thermal equilibration of the cells after their 
transfer from 4°C to 37 °C, the EEA1 level associated with NP containing endosomes in 
Figure 4.5a increased due to enhanced NP-EGF endocytosis and subsequent collection in 
early endosomes at physiological temperatures. The relative EEA1 concentration peaked 
at t = 20 min and then decreased again. Consistent with a maturation of NP containing 
early endosomes into late endosomes, the decrease in EEA1 concentration was 
accompanied by an increase in Rab7a signal. Importantly, the initial drop in EEA1 by 
approximately 60% between t = 20 min and t = 35 min, was followed by a much more 
gradual decrease for t > 35 min. Interestingly, even at t = 80 min, the measured absolute 
EEA1 levels remained significantly higher than the background obtained from controls 
where Au NPs were mixed with cell lysate to account for the unspecific attachment and 
spinning down of the empty endosomes (Figure 4.5b). 
 Although the exact time for the detection of free EGF in the early endosomes 
depends on ligand concentration and receptor expression levels, a typical timescale lies 
between t = 5-20 min after EGF exposure.(Burke, Schooler et al. 2001) The timescale for 
localization of free EGF in the late endosome is between t = 20-60 min.(Burke, Schooler 
et al. 2001) Data in Figure 4.5a shows a slower maturation of NP-EGF containing 
endosomes from the early to late endosomes. It was not before t = 50 min that an increase 
in the Rab7a levels was detected. After that the Rab7a level continued to increase but did 
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not converge until approximately t = 95 min. Even if one takes into account the initial 
delay in uptake associated with the thermal equilibration of the sample, the Rab7a 
increase was still slow. This, together with the detection of NP-EGF in the early 
endosome even after t = 80 min (Figure 4.5), indicates that the dwelling time in the early 
endosomes is significantly longer for NP-EGF than for free EGF. 
 One caveat in the analysis so far is that, although it provides information about 
the distribution of the Au NPs between early and late endosomes as a function of time, it 
is unclear if the NP-EGF remains bound to EGFR over the observed timescale and 
whether the latter remains phosphorylated. Since it is the EGFR* and not the Au NPs per 
se that is responsible for the hypothesized endosomal apoptotic signaling, the EGFR* 
levels associated with NP-EGF at t = 5, 20 and 80 min were evaluated. Again, the 
density-based endosome fractionation approach outlined in Figure 4.4 was used to isolate 
NP containing endosomes. Au NPs on the plasma membrane were removed by etching 
with an aqueous solution of I2/KI (0.34 mM I2 / 2.04 mM KI) at room temperature for 3 
min (Cho, Xie et al. 2009) prior to homogenization of the cells to eliminate any potential 
background from plasma-membrane localized EGFR*. In this way, only intracellular NP-
EGF was collected by centrifugation facilitating a selective quantification of EGFR 
endosomal signaling. To that end, the collected NP containing endosomes were sonicated 
for 10s to further disrupt the endosomal membrane. The NPs released from the 
endosomes were collected by centrifugation and the concentration of EGFR* in the 
supernatant was quantified by ELISA while the Au concentration in the pellet was 
determined by ICP-MS. Figure 4.6 summarizes the relative value of EGFR* level 
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normalized by the uptaken NP concentration at three time points t = 5 min, 20 min and 80 
min. As expected, the EGFR* level was highest (= 100%) at t = 5 min as at this time 
point, most of the collected NP-EGF-EGFR* is in early endosomes with the 
phosphorylated C-terminus available for signaling in the cytosol. With increasing time, 
the measured phosphorylation gradually decreases due to the maturation of NP-EGF-
EGFR* containing endosomes into mature late endosomes or MVBs (Figure 4.5a) where 
the termination of signaling happens by wrapping the NP-EGF-EGFR* with MVB 
membrane or other deactivation processes. After 20 min of incubation, the EGFR* level 
decreased to 47%, and after t = 80 min, the EGFR* level in the NP containing endosome 
fraction further dropped to 33% since more and more NP-EGF-EGFR* complexes 
mature to late endosomes or MVBs as is shown in Figure 4.5a. Interestingly, it is still 
more than 4 fold higher than the cell background where no treatment was used. 
 
 
Figure 4.6. Endosomal Signaling of NP-EGF  
Endosomal EGFR phosphorylation levels induced per NP-EGF at 3 representative time points. Data were 
plotted as a ratio of different chase time to cells chased in fresh DMEM for 5min and were collected from 3 
independent experiments. 
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 Overall, analysis of the isolated NP containing endosomes in a large population of 
MDA-MB-468 cells reveals appreciable levels of NP-EGF and EGFR* in the early 
endosomes for at least 80 min, consistent with the prolonged existence of NP-EGF-
EGFR* complexes capable of signaling in the cytoplasm. 
4.4 Comparison of NP-EGF Trafficking with Free EGF 
 The unambiguous validation of the hypothesis that EGF nanoconjugation 
prolongs the EGFR* dwelling time in early endosomes requires a direct comparison of 
the NP-EGF trafficking dynamics with that of free EGF at comparable effective 
concentrations under similar experimental conditions. As the density-based isolation 
technique is not applicable to the isolation of EGF-EGFR* containing endosomes, a 
conventional optical colocalization strategy was chosen to compare the trafficking 
dynamics of EGF-EGFR* and NP-EGF-EGFR* under the same experimental conditions. 
MDA-MB-468 cells were transfected with Rab5a GFP or Rab7a GFP-constructs to label 
early and late endosomes respectively (Gorvel, Chavrier et al. 1991; Feng, Press et al. 
1995; Nielsen, Severin et al. 1999; Vanlandingham and Ceresa 2009). 80 nm Au NPs can 
serve as a bright probe due to the large scattering cross section and can be easily localized 
in conventional darkfield microscopy. The NP signal in the darkfield microscope can 
then be correlated with the fluorescence signals of the Rab5a or Rab7a labels in wide 
field fluorescence microscopy to determine the NP-EGF colocalization with early or late 
endosomes. For free EGF, an analogous colocalization strategy based on two-color 
confocal fluorescence microscopy was applied. The biotinylated EGF was labeled with 
Alexa 647-functionalized streptavidin in a 1:1 ratio to visualize EGF under confocal 
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fluorescence microscope. By looking for the correlation as a function of time, trafficking 
of NP-EGF and EGF between early and late endosomes can be achieved and compared. 
 MDA-MB-468 cells were transfected with Rab5a and Rab7a GFP-constructs for 
18-22 h at 37 °C to label the early or late endosomes respectively. Old growth medium 
was then replaced with DMEM solutions containing 8 pM NP-EGF (1 nM effective EGF 
concentration) or 1 nM fluorescent EGF for 20 min at 37 °C. NP-EGF or EGF-Alexa 647 
solution was then removed and cells were washed with prewarmed 1% BSA containing 
HBSS and chased in fresh DMEM for 0-280 min prior to fixation with 4% PFA and 
optical analysis. At least 90 cells were analyzed at each individual time and 
representative colocalization images at t = 300 min (20 min incubation + 280 min chase) 
for NP-EGF and at t= 30 min (20 min incubation + 10 min chase) for free EGF are 
provided in Figure 4.6a. The measured Rab5a and Rab7a colocalization probabilities for 
NP-EGF and free EGF throughout the entire observation time are plotted in Figures 4.7b 
and c. The colocalization percentage was determined as the ratio of Rab5a or Rab7a 
positive NP-EGF or EGF to the total number of NP-EGF or EGF within cells. Only cells 
with moderate expression levels of GFP were chosen to decrease the probability of 
coincidental colocalization.  
 For the NP-EGF, the colocalization probability between Au NPs and Rab5a 
positive early endosomes continuously drops from 20 min after removal of the treatment. 
As early endosomes mature to late endosomes, Rab7a positive NP-EGF containing 
endosomes gradually increases and plateaus at 55 min. These results are quite consistent 
with the data obtained from the above endosomal sorting experiments.  
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Figure 4.7. Microscopic Colocalization Study of NP-EGF and Free EGF.  
a. Top: Fluorescence image of Rab5a (green) early endosome marker and darkfield image of NP-EGF (red) 
and computed overlay (yellow) after 5 h incubation. Bottom: Fluorescence image of Rab5a (green) and 
EGF-Alexa 647 (red) and overlay (yellow) after 30 min of incubation (see text). Magnified images for the 
areas in the read squares are included. Scale bar: 10 µm. b. Optical colocalization of NP-EGF with Rab5a 
and Rab7a positive endosomes as a function of time. Data were collected from at least 3 independent 
experiments with a total of ~600 cells analyzed. τ = 83 min r2= 0.86 c. Optical colocalization of EGF-Alexa 
647 with Rab5a and Rab7a positive endosomes as a function of time. Data were collected from at least 3 
independent experiments (~90 cells analyzed). τ = 55min r2= 0.94. 
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 For both NP-EGF and free EGF, the colocalization probability between EGF and 
Rab5a positive early endosomes decreased continuously as a function of time, but the 
decay was faster for the free EGF. The τ of free EGF decay in early endosomes is 55 min 
with r2= 0.94 while for NP-EGF decay, τ is 83 min with r2= 0.83. The observed 
differences in the slope confirm that the dwelling time in early endosomes (Rab5a 
positive) is longer for NP-EGF than for free EGF. Interestingly, a significant amount of 
NP-EGF is still colocalized with Rab5a positive endosomes after more than 4 h chase in 
the fresh growth medium after NP-EGF removal.  
 For both NP-EGF and free EGF, the decrease in Rab5a colocalized NPs or EGF 
was accompanied by increases of Rab7a positive endosomes, consistent with a 
maturation from early to late endosome. While free EGF reached a maximum 
colocalization (~60%) with Rab7a at t = 35 min, which is consistent with literature value 
(20-60 min depends on experimental condition and cell types), it was not before t = 55 
min that NP-EGF plateaued. The delayed transfer from early to late endosome in case of 
NP-EGF is in line with an overall longer dwelling time of the nanoconjugated EGF in the 
early endosomes.  
It is worth noting that the initial overall colocalization probability of NP-EGF 
with Rab5a is much lower compared with the free EGF. It arises from a systematic 
difference between confocal fluorescence and wide field darkfield microscopy. 
Fluorescence confocal microscopy and darkfield microscopy were performed using 
objectives with different numerical apertures (NA). The NA was 1.25 in confocal 
microscopy for free EGF colocalization experiment and 0.65 for darkfield and wide field 
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fluorescence microscopy for NP-EGF colocalization. As the focal depth increases with 
decreasing NA, (Born and Wolf 1980) the background from surface bound objects 
(extracellular NP-EGFs) is much higher in darkfield microscopy than in confocal 
microscopy, which accounts for the overall lower initial colocalization probability for 
NP-EGF with Rab5a positive endosomes. 
4.5 Conclusions 
 In this chapter, a novel endosomal sorting technique based on the density shift of 
the Au containing endosomes was developed to investigate the endosomal accumulation 
and signaling of NP-EGF on an ensemble level of a large population of cells. It can 
successfully collect the NP-EGF containing endosomes and data suggested that NP-EGFs 
travel through the endosomal pathway slower than free EGF, 80 min after the removal of 
NP-EGF, a significant portion of NP-EGF still stays in the early endosomes and remains 
phosphorylated. The decay time of NP-EGF and EGF in early endosomes determined by 
static colocalization method is 83 min and 55 min, respectively, and further demonstrates 
that EGF conjugation to 80 nm diameter Au NPs results in a greatly prolonged dwelling 
time of EGFR* in the early endosomes and slower maturation to the late endosomes than 
the free peptide.  
 Remarkably, a measurable NP-EGF population still remains in the early 
endosomes even after a long chase time (5 h) in the fresh growth medium from the 
microscopic study. However, due to the potential fixation artifacts and false positive 
resulting from the coincidental overlay of two objects in the static colocalization, it is 
uncertain if this Rab5a positive NP-EGF truly reflects the location of NPs. Therefore, a 
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more reliable method which can eliminate the above mentioned bias is needed to verify 
the hypothesis that nanoconjugation is capable of extending the accumulation of EGFR* 
in the early endosomes and thus inducing apoptosis.  
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CHAPTER 5 NP-EGF Intracellular Trafficking 
5.1 Live Cell Imaging and Dynamic Colocalization Microscopy 
 Cellular machinery triggered by engineered NPs involves many species and is a 
highly dynamic process (Brandenburg and Zhuang 2007). It is beneficial to develop a 
robust and reliable experimental setup to track and characterize administered NPs and 
investigate interaction between nanomaterials and cellular components.  
 One important assessment of NPs is their intracellular trafficking. The traditional 
way to map the temporo-spatial distribution of NPs is based on static colocalization in 
which cellular organelles are stained and visualized. The correlation between NPs and 
cellular compartments of interest is conducted based on static images at recorded 
moments. However, the coincidental overlay of two objects can overestimate the 
colocalization percentage. The localization accuracy for an individual emitter in optical 
microscopy is determined by the diffraction limit. The lateral spatial resolution of an 
optical system is given as ~ 0.6λ/NA, where λ is the wavelength of the light and NA is 
the numerical aperture. Even for confocal microscopy, in which this limit is pushed to 
0.4λ/NA, the lateral resolution on the focal plane is still in the few hundreds of 
nanometers range with illumination of visible light. Axial resolution is always less than 
the x and y due to the blurring effect of the point spread function (PSF) (Huang, Bates et 
al. 2009). In practice, the resolution in the z axis is about 500-700 nm. It is hard to give 
very precise location in z direction which, in turn, increases the probability of 
coincidental overlay and false positives. In order to improve the accuracy of the 
colocalization of NPs with cellular compartments, dynamic colocalization microscopy 
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based on single particle tracking has been developed (Vercauteren, Deschout et al. 2011). 
It is capable of simultaneously tracking two or more objects and visualizing the 
interactions in an intuitive fashion. By correlating the spatial trajectories of the tracked 
objects (i.e.. dynamic colocalization), this method can greatly improve the reliability of 
the detection of interactions between moving objects compared with static colocalization, 
where false positives are hard to avoid due to the coincidental overlap (Levi and Gratton 
2007; Braeckmans, Buyens et al. 2010; Vercauteren, Deschout et al. 2011). Since 
dynamic colocalization specifically searches for correlated movement and it is done with 
living cells, it can also eliminate the artifact introduced by fixation of cells during 
immunostaining steps in static colocalization method (Comeau, Costantino et al. 2006). 
 A traditional implementation of dynamic colocalization microscopy and single 
particle tracking is based on dual- or multi-color fluorophore colocalization. 
Fluorophores with separate wavelengths can be imaged independently on different color 
channels (Lacoste, Michalet et al. 2000), allowing the simultaneous tracking of 
fluorescent NPs and labeled cellular components to reveal direct interactions. So far, this 
technique is exclusively based on fluorescently labeled NPs and the limitation of the 
fluorescent dye restrains the application of this method. Limited photophysical stability 
of fluorescent dyes lead to an irreversible loss of fluorescence due to chemical 
transformation caused by photoexcitaion (Cooper, Uhm et al. 2013; Wu and Reinhard 
2014). It fundamentally limits the ability to monitor cellular dynamics continuously over 
extended periods of time with high temporal resolution. Also, important NPs of interest 
in (bio)nanotechnology are not necessarily fluorescent; for example, gold NPs. They are 
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highly biocompatible (Shukla, Bansal et al. 2005; Murphy, Gole et al. 2008), have well 
established shape- and size-specific synthesis (Xia, Xiong et al. 2009; Ziegler and 
Eychmuller 2011), easy surface modification strategies (Sapsford, Algar et al. 2013) and 
offer unique photophysical stability and resonant scattering cross-sections that are several 
times larger than their physical size. As their emission is based on elastic scattering, gold 
NPs offer bright and stable signals and those are beneficial for an accurate localization of 
the tracked species, even at short acquisition times. 
 Therefore, in this chapter, an alternative optical imaging approach that combines 
the advantages of metal NP tracking in darkfield microscopy with the versatility of a 
simultaneous fluorescence tracking of cellular components was developed. Dynamic 
trajectory correlation of the fluorescence signal of GFP-tagged Rab5 as markers for early 
endosomes with the elastic scattering signal of gold NPs was utilized for characterizing 
the trafficking of epidermal growth factor (EGF) functionalized NPs in early endosomes 
to improve the accuracy of static colocalization experiment conducted in chapter 4 and 
prove the hypothesis of the prolonged dwelling time of NP-EGF-EGFR* in the early 
endosomes leading to apoptosis.  
5.2 Implementation and Experimental Setup 
5.2.1 Optical Setup 
 The excitation and emission spectra of GFP and the scattering spectrum of the 
80nm diameter Au NPs are shown in Figure 5.1. GFP has a major excitation peak at a 
wavelength of 488nm and the emission peak is at 510nm. The spectra of 80 nm NPs after  
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Figure 5.1. Spectra of GFP and NP-EGF.  
Excitation (green) and emission (orange) spectra of GFP and UV-Vis spectrum of 80nm NP-EGF (grey) in 
1X PBS. 
 
functionalized with EGF was taken with UV-Vis in 1X PBS buffer and peaks at 570 nm. 
A comparison of the GFP fluorescence and NP scattering spectra indicates that at 600 
nm, fluorescent emission is comparably weak while the scattering of NPs is still strong. 
Therefore, it is possible to use a dichroic filter with a cut-off wavelength of 580 nm 
(dashed line in Figure 5.1) to separate the emitted fluorescence signal from the early 
endosomes and the scattered light at 600 nm from NP-EGF. The experimental set-up for 
correlated darkfield and fluorescence tracking of NPs and GFP-tagged endosomes is 
shown in Figure 5.2a. Whitelight from a Tungsten lamp passes a bandpass filter (cut-on 
wavelength: 600 nm ± 10 nm) and is then injected into the imaging plane at oblique 
angles using a high numerical aperture (NA = 1.2-1.4) darkfield condenser from one side  
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Figure 5.2. Experimental Setup and Representative Trajectories.  
a. Optical setup for correlated fluorescence/darkfield tracking. NP-EGFs are illuminated by a tungsten lamp 
with a 600 ± 10 nm bandpass filter. The GFP associated with Rab5a is excited at 480 ± 17 nm and the 
emission is collected at 510 ± 10 nm. The light collected from NPs and GFP is split by a dichroic 
(transmission/reflection transition at 580 nm) and detected with two separate EMCCDs. 1. 600 ± 10 nm 
bandpass filter. 2. Oil / Water condenser. 3. 495 nm dichroic. 4. 580 nm dichroic. 5. 600 ± 10 nm bandpass 
filter.  6. 480 ± 17 nm bandpass filter. 7. 510 ± 10 nm bandpass filter. b. Representative fluorescence / 
darkfield trajectories (60s) of colocalized Rab5a-GFP (green) and NP-EGF (red). 
 
of the sample to excite the surface plasmon of the 80nm NP-EGF. From the opposite 
side, a monochromatic excitation source of 480nm ± 17 nm is focused on the imaging 
plane through a 60x objective (NA = 0.65). This objective collects both the light scattered 
from NPs in the focal plane (600nm ± 10 nm), as well as the emitted light from 
fluorescent probes (510nm ± 10 nm). The NA of the objective was 0.65 to offer high 
contrast in darkfield and adequate light detection in fluorescence. The light collected by 
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the objective is chromatically split using the 580 nm dichroic. Fluorescence and NP 
scattering images are recorded on two separate electron multiplying charge coupled 
devices (EMCCD). In some fluorescence applications, it has become common practice to 
use image splitters to monitor different wavelengths at different areas of the same 
(EM)CCD detector. However, due to the large intensity differences between NP-EGF 
scattering in the darkfield microscopy and GFP signal from the fluorescence images, the 
one camera approach is not applicable in correlated darkfield/fluorescence microscopy. 
Instead, two synchronized EMCCD detectors with a chip size of 128×128 pixel and a 
pixel size of 312.5 nm were used. The use of two cameras allowed for an independent 
optimization of the enhancement factors for the two separate channels. 
5.2.2 Detection of Correlated Movement between Two Objects 
 Dynamic colocalization is specifically searching for correlation between two 
trajectories. In the experiment, a movie of length of N (N=120) frames was taken 
simultaneously for NP-EGF and Rab5a-GFP from each channel at 0.5 fps. Trajectories of 
NP-EGFs (from the scattering channel) and early endosomes (from the fluorescent 
Rab5a-GFP channel) were generated. At each frame i (i=1, 2, 3, …, N), the x and y 
coordinates of the points in the fluorescent trajectory and scattering trajectory xf,i, yf,i, xs,i, 
ys,i were calculated with Gaussian fit of PSF. The Pearson product-moment correlation 
coefficient (𝜌) was utilized to quantify the correlation between the NP-EGF and the 
corresponding early endosome trajectories. It is defined as the quotient of the covariance 
of two variables divided by their standard deviations. The Pearson correlation coefficient 
can be calculated as: 
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where ?̅?𝑓, ?̅?𝑠 , ?̅?𝑓 and ?̅?𝑠 are the average x and y positions in the fluorescent and scattering 
trajectories of a single point, respectively. 𝜌 is in the range from −1 to +1, where −1 is 
total negative correlation while +1 is total positive correlation and 0 is random, no 
correlation. A threshold of 0.5 was chosen to determine the correlated points as the 
positive control reaches 98% while the genitive control is 0% (Vercauteren, Deschout et 
al. 2011). NP-EGF and Rab5a whose 𝜌𝑥 and 𝜌𝑦 of the trajectories are larger than the 
chosen threshold are defined as correlated particles. 
5.3 NP-EGF Intracellular Trafficking 
 In chapter 4, a very gradual decrease of optical colocalization between NP-EGF 
and Rab5a shown in Figure 4.6b suggests that even after several hours chase in the fresh 
growth medium, a measurable fraction of NP-EGF still remains in the early endosomes of 
MDA-MB-468 cells. However, static colocalization studies contain an error from 
coincidental colocalization, especially in the case of darkfield microscopy, which is 
typically performed at lower NAs than fluorescence microscopy. Particularly at low NP 
concentrations, the error from coincidental colocalization can be significant. Therefore, 
the dynamic colocalization microscopy based on the scattering of Au NPs and 
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fluorescence of Rab5a-GFP construct that discussed above was used to independently 
verify the very long dwelling time of NP-EGF in early endosomes. The idea underlying 
this approach is to minimize coincidental colocalization and, thus, to improve the 
reliability of detecting interactions between moving objects by correlating entire 
trajectories of tracked objects. 
 For the tracking studies, MDA-MB-468 cells were first transfected with Rab5a-
GFP construct to label early endosomes for 18-20 h. Cells were then washed with 
prewarmed DMEM twice and incubated with 4 pM NP-EGF for 20 min in growth 
medium at 37 °C. The NP-EGF solution was removed and cells were further chased for 
up to 250 min (total time approx. 4.5 h) at 37 °C in fresh DMEM. After a defined chase 
time, movies with a frame rate of 2 s-1 were taken simultaneously on the fluorescent 
channel (Rab5a marked endosomes) and the darkfield channel (NP-EGF) for a total 
length of 120 frames in the incubator mounted on the microscope to keep the temperature 
at 37 °C. Only cells with moderate expression level of Rab5a-GFP and NP-EGF uptake 
were chosen for movies to reduce the background and improve the precision of tracking. 
For every movie, a new cell was selected to minimize photo damage to the fluorescently 
labeled early endosomes. The recorded movies allowed for the tracking of selected 
objects throughout the field of view on both the fluorescence and darkfield channels. 
Snapshots at selected frames of darkfield and fluorescence images in a typical dynamic 
colocalization movie of MDA-MB-468 cells after 4.5 h chase in DMEM are shown in 
Figure 5.3. Green represents the Rab5a in the fluorescent channel and red is the NP-EGF 
from the scattering channel. After removal of NP-EGF and 4.5 h chase in DMEM, most  
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Figure 5.3. Snapshots of NP-EGF and Rab5a Colocalization.  
Snapshots of a movie showing colocalization of Rab5a-GFP (green) and NP-EGF (red). Scale bar: 10 µm. 
 
of NP-EGF didn’t show any colocalization with fluorescent signals. Some of NP-EGF 
shows coincidental overlay with Rab5a-positive endosomes in some of the frames while 
delocalized in others (Figure 5.3, labeled with 5-6). However, the images also 
demonstrated a continuing colocalization of NP-EGF and fluorescent labeled early 
endosomes over extended periods of time for selected particles (Figure 5.3, labeled with 
1-4), suggesting that these NPs are potentially localized in Rab5a positive endosomes. 
For this population of NP-EGF that showed a colocalization with Rab5a at any time 
throughout the movie, the trajectories of NP-EGF and corresponding Rab5a were 
generated with Gaussian fitting to find the coordinates of the associated point-spread-
functions on the two monitored channels throughout the entire duration of the movie (~60 
s). The Pearson product-moment correlation coefficients described above were then 
calculated for the two corresponding trajectories. In this way, a quantification of the 
spatial correlation between NP and endosome trajectories was achieved.(Vercauteren, 
Deschout et al. 2011) Figure 5.2b contains an example of correlated Rab5a and NP-EGF 
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trajectories recorded at t = 4.5 h, which shows a high correlation in the movement of both 
x-axis and y-axis of the coordinates. Correlation of trajectories was checked for all NP-
EGF that showed positive in Rab5a channel. The colocalization percentage was then 
calculated as the ratio of the number of Rab5a correlated NP-EGF to the total NP-EGF in 
the field of view at the first frame of the scattering channel for different chase time (t= 
30min and t=4.5h). 
 
 
Figure 5.4. Colocalization Percentage of NP-EGF and Rab5a.  
Colocalization percentage of NP-EGF with Rab5a-GFP determined by dynamic colocalization microscopy 
at two selected time points (30min and 4.5h). 
 
 Quantification of the colocalization of Rab5a and NP-EGF signal through 
dynamic colocalization analysis at different time points revealed that the Rab5a 
colocalization with NP dropped from 48% ± 2.5% at t = 30 min to 10% ± 1% at t = 4.5 h 
(Figure 5.4). This finding corroborates the conclusion from our static colocalization 
studies. NP-EGF decays in early endosomes along with time due to the endosome 
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maturation. But a small population of NP-EGF remains in the early endosomes even 
hours after NP-EGF removal in the growth medium. 
5.4 Conclusion 
 In this chapter, dynamic colocalization microscopy based on the scattering signal 
from NP-EGF and fluorescent signal from the Rab5a-GFP has been developed and 
performed to study the prolonged dwelling time of NP-EGF in early endosomes. The 
trajectory-based correlation significantly improves the accuracy of colocalizaion by 
decreasing the false positives in the static image colocalization due to the coincidental 
overlay. With this improved technique, 10% of NP-EGFs are still found in the Rab5a 
positive endosomes after 4.5 h, which verifies that a significant amount of NP-EGF are 
trapped in the early endosomes even after hours of chase time in fresh growth medium. 
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CHAPTER 6 Conclusion 
 Spatial control through trafficking is anticipated to be a common aspect of 
intracellular signaling for a broad range of transmembrane receptors. EGF is a growth 
factor that stimulates cell growth and differentiation under native conditions but can also 
induce apoptosis in EGFR overexpressing cells. In this thesis, detailed experimental 
evidence has been provided that a covalent attachment of the EGF peptide to pegylated 
40 nm and 80 nm diameter Au NPs results in an enhancement of apoptotic efficacy in 
EGFR overexpressed cell lines (A431and MDA-MB-468), and even in cells with 
physiological level of EGFR expression which are not known to show apoptosis in 
response to high dosage of free EGF (HeLa). It indicates that nanoconjugation can 
modulate apoptosis associated cellular regulation mechanisms. 
 In order to understand the underlying mechanism of this nanoconjugation 
enhanced apoptosis, the impact of nanoconjugation on the intracellular spatial and 
temporal distribution of EGF-EGFR* containing endosomes was investigated. 80 nm NP-
EGF was selected towards this goal because of its superb optical properties and stronger 
ability to induce EGF mediated apoptosis when compared with 40 nm Au. Internalization 
and trafficking of 80 nm diameter NP-EGF was investigated with two orthogonal 
experimental approaches. The first took advantage of the increased density of endosomes 
associated with the uptake of Au NPs to isolate NP-EGF-EGFR* containing endosomes 
and the distribution of NP-EGF-EGFR between early and late endosomes was determined 
with ELISA. The second approach was based on correlated darkfield/fluorescence 
imaging to map the spatial distribution of NP-EGF-EGFR* containing endosomes as a 
  
81 
function of time through the endosomal pathway. These studies revealed that 80nm NP-
EGF enters the investigated MDA-MB-468 cells through a clathrin-dependent pathway 
and a slower decay of NP-EGF in the early endosomes was observed. Even after a short 
(20 min) exposure to a relatively low concentration (8 pM) of NP-EGF (effective EGF 
concentration ≈ 1 nM ), a non-negligible fraction of NP-EGF was found to remain in 
early endosomes for at least 5 hours. To further validate the long retention time of NP-
EGF in early endosomes, a dynamic colocalization microscopy based on scattering of 
NP-EGF and fluorescence of Rab5a-GFP construct was developed. The nanoconjugation 
impacts to the subsequent trafficking of EGF and EGF-EGFR* signaling are summarized 
in Figure 6.1. This long retention time of NP-EGF in the early endosomes provides a 
platform for tethered EGF-EGFR* to initiate cytoplasmic signaling over extended periods 
of time and was accompanied by a strong enhancement of EGF-mediated apoptosis. The 
finding that this temporo-spatial regulation nature of EGFR signaling is susceptible to 
ligand nanoconjugation suggests nanoconjugation as a general tool for modulating 
trafficking outcomes. 
 Nanoconjugation induced apoptosis is not unique to EGF but has also been 
observed for a few other ligands, such as transferrin (Wang, Tian et al. 2010). In the case 
of transferrin, the apoptotic effect was associated with a clathrin-independent endocytosis 
and trafficking to the acidic compartments that are free of EEA1 and LAMP1 induced by 
multivalent presentation of the ligand. However, in the NP-EGF case, like the free ligand, 
the internalization is dominated by clathrin-dependent pathway. Instead, the retention of 
NP-EGF in early endosomes and the slow maturation from the early endosomes into late 
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endosomes are overall consistent with the previously identified mechanism of free EGF 
mediated apoptosis (Rush, Quinalty et al. 2012) . The major difference is that NP-EGF 
requires significantly lower threshold concentrations to be effective and is independent 
from the expression level of EGFR. 
 Nanoconjugation has been shown before to support the apoptotic effect of some 
anticancer drugs due to targeted delivery, enhanced cell permeabilization or related 
mechanisms (Khdair, Chen et al. 2010; Vandita, Shashi et al. 2012; Zhang, Li et al. 
2013). EGF nanoconjugation induced apoptosis differs, however, fundamentally from the 
above cases since EGF is an endogenous growth factor that stimulates proliferation under 
native conditions. The selective enrichment of circulating NPs in tumor tissue due to the 
well-known enhanced permeability and retardation (EPR) effect (Cho, Wang et al. 2008; 
Maeda 2010), and the active targeting to the EGFR by the EGF on NPs surface, together 
with the demonstrated ability to enhance the apoptotic efficacy of EGF through 
nanoconjugation in vitro, provides a new potential strategy for overcoming apoptosis 
evasion in cancer cells. 
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Figure 6.1. Intracellular Trafficking of NP-EGF and Free EGF  
Colocalization percentage of NP-EGF with Rab5a determined by dynamic colocalization microscopy at 
two selected time points (30min and 4.5h). Intracellular trafficking of NP-EGF and free EGF.  NP-EGF and 
EGF bind to EGFR on the plasma membrane, activate EGFR and then induce clathrin-mediated 
endocytosis that trafficks EGF and the bound receptor from the early endosomes (EE) to the multivesicular 
bodies (MVB) of the late endosome. EGF nanoconjugation induce longer dwelling time (83min) for NP-
EGF-EGFR* in the early endosomes, prolonging endosomal EGFR signaling and inducing apoptosis. 
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APPENDIX 
i Matlab code for overlay two movies 
prompt = 'What is the background x in F? '; 
bkgF_x = input(prompt); 
prompt = 'What is the background y in F? '; 
bkgF_y = input(prompt); 
  
prompt = 'What is the background x in D? '; 
bkgD_x = input(prompt); 
prompt = 'What is the background y in D? '; 
bkgD_y = input(prompt); 
  
prompt = 'What is x right shift? ';  
shift_x = input(prompt); 
prompt = 'What is y down shift? ';   
shift_y = input(prompt); 
  
for i=1:length 
    tempoF=movieF(:,:,i); 
    if bkgF_y==0 
        tempoF=tempoF; 
    else 
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    tempoF=tempoF-movieF(bkgF_y,bkgF_x,i); 
    tempoF(find(tempoF<0))=0; 
    end 
  
     tempoD=movieD(:,:,i); 
     
    if bkgD_y==0 
        tempoD=tempoD; 
    else 
    tempoD=tempoD-movieD(bkgD_y,bkgD_x,i); 
    tempoD(find(tempoD<0))=0; 
    end 
     
    tempoF_shift=circshift(tempoF, [shift_y, shift_x]);   
     
    if shift_y>0   
        tempoF_shift(1:shift_y,:)=0; 
    elseif shift_y<0 
        tempoF_shift(128+shift_y:128,:)=0; 
    else 
    end 
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    if shift_x>0   
        tempoF_shift(:,1:shift_x)=0; 
    elseif shift_x<0 
        tempoF_shift(:,128+shift_x:128)=0; 
    else 
    end    
    moviergb(:,:,2,i)=tempoF_shift/max(tempoF_shift(:))/2; 
    moviergb(:,:,1,i)=tempoD/max(tempoD(:)); 
    moviergb(:,:,3,i)=zeros; 
end 
mov=immovie(moviergb); 
movie2avi(mov, 'overlay.avi', 'compression', 'None','fps',15) 
implay(mov, 5) 
 
ii Matlab code for dynamic colocalization processing 
trajectory=zeros(length,2); 
prompt = 'What is the x in andor? '; 
NP_x = input(prompt); 
prompt = 'What is the y in andor? '; 
NP_y = input(prompt); 
FitA=3;  
NP_coordinates=zeros(length,2); 
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NP_coordinates(1,1:2)=[NP_y,NP_x];  
NP_location=zeros(FitA,FitA,length); 
 
NP_location(:,:,1)=movie(NP_coordinates(1,1)-(FitA-1)/2:NP_coordinates(1,1)+(FitA-
1)/2,NP_coordinates(1,2)-(FitA-1)/2:NP_coordinates(1,2)+(FitA-1)/2,1);  
r=zeros(length,1);  
x=1:FitA;y=1:FitA; 
h = waitbar(0,'gaussian fitting'); 
for i=1:length 
    h=waitbar(i/length); 
    [fitresult,gof]=GFit_plus_bg(x,y,NP_location(:,:,i));   
    c=coeffvalues(fitresult);   
    r(i,1)=gof.rsquare; 
    trajectory(i,1)=NP_coordinates(i,1)+c(6)-(FitA+1)/2;  
    trajectory(i,2)=NP_coordinates(i,2)+c(5)-(FitA+1)/2; 
        break; 
    else 
    temp(:,:,i)=movie(NP_coordinates(i,1)-1:NP_coordinates(i,1)+1,NP_coordinates(i,2)-
1:NP_coordinates(i,2)+1,i+1); 
    tempo(:,:,1)=temp(:,:,i); 
    a=max(tempo(:));   
    ind = find(tempo==a); 
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    [y_coordinate,x_coordinate,frame] = ind2sub([3 3 1],ind); 
     
    NP_coordinates(i+1,1)=NP_coordinates(i,1)-2+y_coordinate(1,1); 
     NP_coordinates(i+1,2)=NP_coordinates(i,2)-2+x_coordinate(1,1); 
     
    t=size(y_coordinate);     
    if t(1,1)>1 
        mindistance=12; 
        for j=1:t(1,1) 
            distance(j,1)=(y_coordinate(j,1)-3)^2+(x_coordinate(j,1)-3)^2; 
            if distance(j,1)<mindistance 
                mindistance=distance(j,1); 
                y_coordinate_new=y_coordinate(j,1); 
                x_coordinate_new=x_coordinate(j,1); 
            else 
            end 
        end 
        NP_coordinates(i+1,1)=NP_coordinates(i,1)-3+y_coordinate_new; 
        NP_coordinates(i+1,2)=NP_coordinates(i,2)-3+x_coordinate_new; 
    else 
    NP_coordinates(i+1,1)=NP_coordinates(i,1)-3+y_coordinate; 
    NP_coordinates(i+1,2)=NP_coordinates(i,2)-3+x_coordinate; 
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    end 
NP_location(:,:,i+1)=movie(NP_coordinates(i+1,1)-(FitA-
1)/2:NP_coordinates(i+1,1)+(FitA-1)/2,NP_coordinates(i+1,2)-(FitA-
1)/2:NP_coordinates(i+1,2)+(FitA-1)/2,i+1); 
    end 
end 
close(h) 
figure 
imagesc(movie(:,:,1)); colormap('gray'); 
hold on; 
plot(trajectory(:,2),trajectory(:,1),'y','linewidth',2) 
 
iii Matlab code for Pearson correlation 
number=120; 
x_d_av=mean(trajectory_s(:,1)); 
x_f_av=mean(trajectory_s(:,3)); 
y_d_av=mean(trajectory_s(:,2)); 
y_f_av=mean(trajectory_s(:,4)); 
up_x=0;lowx_left=0; lowx_right=0; 
up_y=0;lowy_left=0; lowy_right=0; 
coeff=zeros(1:number,1:2); 
for i=1:number 
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    up_x=up_x+(trajectory_s(i,1)-x_d_av)*(trajectory_s(i,3)-x_f_av); 
    up_y=up_y+(trajectory_s(i,2)-y_d_av)*(trajectory_s(i,4)-y_f_av); 
    lowx_left=lowx_left+(trajectory_s(i,1)-x_d_av)^2; 
    lowx_right=lowx_right+(trajectory_s(i,3)-x_f_av)^2; 
    lowy_left=lowy_left+(trajectory_s(i,2)-y_d_av)^2; 
    lowy_right=lowy_right+(trajectory_s(i,4)-y_f_av)^2; 
    coeff(i,1)=up_x/sqrt(lowx_left*lowx_right); 
    coeff(i,2)=up_y/sqrt(lowy_left*lowy_right); 
end 
figure 
plot(1:number,coeff(:,1),'r','linewidth',4); hold on; 
plot(1:number,coeff(:,2),'g','linewidth',4) 
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